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Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14751. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled
receptors, ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools,
alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2019,
and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union
of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug
targets, where appropriate.
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Overview: Catalytic receptors are cell-surface proteins, usually
dimeric in nature, which encompass ligand binding and func-
tional domains in one polypeptide chain. The ligand bind-
ing domain is placed on the extracellular surface of the plasma
membrane and separated from the functional domain by a single
transmembrane-spanning domain of 20-25 hydrophobic amino
acids. The functional domain on the intracellular face of the
plasma membrane has catalytic activity, or interacts with particu-
lar enzymes, giving the superfamily of receptors its name. Endoge-
nous agonists of the catalytic receptor superfamily are peptides or
proteins, the binding of which may induce dimerization of the
receptor, which is the functional version of the receptor.
Amongst the catalytic receptors, particular subfamilies may be
readily identiﬁed dependent on the function of the enzymatic
portion of the receptor. The smallest group is the particulate
guanylyl cyclases of the natriuretic peptide receptor family. The
most widely recognized group is probably the receptor tyrosine ki-
nase (RTK) family, epitomized by the neurotrophin receptor fam-
ily, where a crucial initial step is the activation of a signalling
cascade by autophosphorylation of the receptor on intracellular
tyrosine residue(s) catalyzed by enzyme activity intrinsic to the
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receptor. A third group is the extrinsic protein tyrosine kinase
receptors, where the catalytic activity resides in a separate pro-
tein from the binding site. Examples of this group include the
GDNF and ErbB receptor families, where one, catalytically silent,
member of the heterodimer is activated upon binding the ligand,
causing the second member of the heterodimer, lacking ligand
binding capacity, to initiate signaling through tyrosine phos-
phorylation. A fourth group, the receptor threonine/serine ki-
nase (RTSK) family, exempliﬁed by TGF-β and BMP receptors,
has intrinsic serine/threonine protein kinase activity in the het-
erodimeric functional unit. A ﬁfth group is the receptor tyrosine
phosphatases (RTP), which appear to lack cognate ligands, but
may be triggered by events such as cell:cell contact and have iden-
tiﬁed roles in the skeletal, hematopoietic and immune systems.
A further group of catalytic receptors for the Guide is the inte-
grins, which have roles in cell:cell communication, often associ-
ated with signaling in the blood.
Family structure
S248 Cytokine receptor family
S249 IL-2 receptor family
S251 IL-3 receptor family
S252 IL-6 receptor family
S254 IL-12 receptor family
S255 Prolactin receptor family
S256 Interferon receptor family
S257 IL-10 receptor family
S258 Immunoglobulin-like family of IL-1 receptors
S259 IL-17 receptor family
S259 GDNF receptor family
S260 Integrins
S264 Pattern recognition receptors
S264 Toll-like receptor family
S266 NOD-like receptor family
S268 RIG-I-like receptor family
S269 Receptor guanylyl cyclase (RGC) family
S269 Transmembrane guanylyl cyclases
S270 Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
– Receptor kinases
– TK: Tyrosine kinase
S271 Receptor tyrosine kinases (RTKs)
S272 Type I RTKs: ErbB (epidermal growth
factor) receptor family
S273 Type II RTKs: Insulin receptor family
S274 Type III RTKs: PDGFR, CSFR, Kit,
FLT3 receptor family
S275 Type IV RTKs: VEGF (vascular endothelial
growth factor) receptor family
S275 Type V RTKs: FGF (ﬁbroblast growth factor)
receptor family
S276 Type VI RTKs: PTK7/CCK4
S277 Type VII RTKs: Neurotrophin receptor/
Trk family
S278 Type VIII RTKs: ROR family
S278 Type IX RTKs: MuSK
S279 Type X RTKs: HGF (hepatocyte growth
factor) receptor family
S279 Type XI RTKs: TAM (TYRO3-, AXL-
and MER-TK) receptor family
S280 Type XII RTKs: TIE family of angiopoietin
receptors
S280 Type XIII RTKs: Ephrin receptor family
S281 Type XIV RTKs: RET
S282 Type XV RTKs: RYK
S282 Type XVI RTKs: DDR (collagen receptor)
family
S283 Type XVII RTKs: ROS receptors
S283 Type XVIII RTKs: LMR family
S284 Type XIX RTKs: Leukocyte tyrosine kinase
(LTK) receptor family
S284 Type XX RTKs: STYK1
– TKL: Tyrosine kinase-like
S286 Receptor serine/threonine kinase (RSTK) family
S286 Type I receptor serine/threonine kinases
S287 Type II receptor serine/threonine kinases
S287 Type III receptor serine/threonine kinases
S287 RSTK functional heteromers
S289 Receptor tyrosine phosphatase (RTP) family
S291 Tumour necrosis factor (TNF) receptor family
Cytokine receptor family
Catalytic receptors→ Cytokine receptor family
Overview: Cytokines are not a clearly deﬁned group of agents,
other than having an impact on immune signalling pathways, al-
though many cytokines have effects on other systems, such as in
development. A feature of some cytokines, which allows them to
be distinguished from hormones, is that they may be produced
by “non-secretory” cells, for example, endothelial cells. Within
the cytokine receptor family, some subfamilies may be identi-
ﬁed, which are described elsewhere in the Guide to PHARMA-
COLOGY, receptors for the TNF family, the TGF-β family and the
chemokines. Within this group of records are described Type I
cytokine receptors, typiﬁed by interleukin receptors, and Type II
cytokine receptors, exempliﬁed by interferon receptors. These
receptors possess a conserved extracellular region, known as the
cytokine receptor homology domain (CHD), along with a range
of other structural modules, including extracellular immunoglob-
ulin (Ig)-like and ﬁbronectin type III (FBNIII)-like domains, a
transmembrane domain, and intracellular homology domains.
An unusual feature of this group of agents is the existence of
soluble and decoy receptors. These bind cytokines without al-
lowing signalling to occur. A further attribute is the produc-
tion of endogenous antagonist molecules, which bind to the
receptors selectively and prevent signalling. A commonality of
these families of receptors is the ligand-induced homo- or hetero-
oligomerisation, which results in the recruitment of intracellular
protein partners to evoke cellular responses, particularly in inﬂam-
matory or haematopoietic signalling. Although not an exclusive
signalling pathway, a common feature of the majority of cytokine
receptors is activation of the JAK/STAT pathway. This cascade is
based around the protein tyrosine kinase activity of the Janus
kinases (JAK), which phosphorylate the receptor and thereby
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facilitate the recruitment of signal transducers and activators of
transcription (STATs). The activated homo- or heterodimeric
STATs function principally as transcription factors in the nucleus.
Type I cytokine receptors are characterized by two pairs of
conserved cysteines linked via disulﬁde bonds and a C-terminal
WSXWS motif within their CHD. Type I receptors are commonly
classiﬁed into ﬁve groups, based on sequence and structual ho-
mology of the receptor and its cytokine ligand, which is poten-
tially more reﬂective of evolutionary relationships than an earlier
scheme based on the use of common signal transducing chains
within a receptor complex.
Type II cytokine receptors also have two pairs of conserved
cysteines but with a different arrangement to Type I and also lack
the WSXWS motif.
IL-2 receptor family
Catalytic receptors→ Cytokine receptor family→ IL-2 receptor family
Overview: The IL-2 receptor family consists of one or more ligand-selective subunits, and a common γ chain (γc): IL2RG, P31785), though IL-4 and IL-7 receptors can form complexes with other receptor
chains. Receptors of this family associate with Jak1 and Jak3, primarily activating Stat5, although certain family members can also activate Stat1, Stat3, or Stat6. Ro264550 has been described as a selective
IL-2 receptor antagonist, which binds to IL-2 [211].
Nomenclature Interleukin-2 receptor Interleukin-4 receptor type I Interleukin-4 receptor type II Interleukin-7 receptor Interleukin-9 receptor
Subunits Interleukin-4 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)
Interleukin-13 receptor subunit α1
(Other subunit)
Interleukin-4 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)
Interleukin-7 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)
Interleukin 9 receptor
(Ligand-binding subunit),
Endogenous agonists IL-2 (IL2, P60568) IL-4 (IL4, P05112) IL-13 (IL13, P35225), IL-4 (IL4,
P05112)
IL-7 (IL7, P13232) IL-9 (IL9, P15248)
Endogenous antagonists IL-1 receptor antagonist (IL1RN,
P18510)
– – – –
Selective antagonists AF12198 [1] – – – –
Searchable database: http://www.guidetopharmacology.org/index.jsp IL-2 receptor family S249
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Interleukin-2 receptor subunit β
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ
(Other subunit)
Interleukin-2 receptor subunit α
(Ligand-binding subunit),
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Nomenclature Interleukin 13 receptor, α2 Interleukin-15 receptor Interleukin-21 receptor Thymic stromal lymphopoietin receptor
HGNC, UniProt IL13RA2, Q14627 – – –
Subunits – Interleukin-2 receptor subunit β
(Ligand-binding subunit),
Interleukin-15 receptor subunit α
(Ligand-binding subunit),
Interleukin-2 receptor subunit γ (Other
subunit)
Interleukin-2 receptor subunit γ
(Other subunit) Cytokine receptor-like factor 2 (Other
subunit)
Interleukin-7 receptor subunit α
(Ligand-binding subunit),
Endogenous agonists – IL-15 (IL15, P40933) [253] IL-21 (IL21, Q9HBE4) thymic stromal lymphopoietin (TSLP,
Q969D9)
Comments Decoy receptor that binds IL-13 (IL13,
P35225) as a monomer.
– – –
Subunits
Nomenclature Interleukin-2 receptor subunit α Interleukin-2 receptor subunit β Interleukin-2 receptor subunit γ Interleukin-4 receptor subunit α Interleukin-7 receptor subunit α
HGNC, UniProt IL2RA, P01589 IL2RB, P14784 IL2RG, P31785 IL4R, P24394 IL7R, P16871
Antibodies daclizumab (Binding) (pKd >8)
[182], basiliximab (Binding)
– – dupilumab (Binding) (pIC50 11.1)
[146]
–
Nomenclature Interleukin 9 receptor Interleukin-13 receptor subunit α1 Interleukin-15 receptor subunit α Interleukin 21 receptor Cytokine receptor-like factor 2
HGNC, UniProt IL9R, Q01113 IL13RA1, P78552 IL15RA, Q13261 IL21R, Q9HBE5 CRLF2, Q9HC73
Further reading on IL-2 receptor family
Leonard WJ et al. (2019) The γc Family of Cytokines: Basic Biology to Therapeutic Ramiﬁcations
Immunity 50: 832-850
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IL-3 receptor family
Catalytic receptors→ Cytokine receptor family→ IL-3 receptor family
Overview: The IL-3 receptor family signal through a receptor complex comprising of a ligand-speciﬁc α subunit and a common β chain (CSF2RB, P32927), which is associated with Jak2 and signals
primarily through Stat5.
Nomenclature Interleukin-3 receptor Interleukin-5 receptor Granulocyte macrophage colony-stimulating factor receptor
Subunits Interleukin 3 receptor, α subunit (Ligand-binding subunit),
Cytokine receptor common β subunit (Other subunit)
Interleukin 5 receptor, α subunit (Ligand-binding subunit),
Cytokine receptor common β subunit (Other subunit)
GM-CSF receptor, α subunit (Ligand-binding subunit),
Cytokine receptor common β subunit (Other subunit)
Endogenous agonists IL-3 (IL3, P08700) IL-5 (IL5, P05113) G-CSF (CSF3, P09919), GM-CSF (CSF2, P04141)
Selective antagonists – YM90709 [159] –
Subunits
Nomenclature Interleukin 3 receptor, α subunit Interleukin 5 receptor, α subunit GM-CSF receptor, α subunit Cytokine receptor common β subunit
HGNC, UniProt IL3RA, P26951 IL5RA, Q01344 CSF2RA, P15509 CSF2RB, P32927
Endogenous agonists IL-3 (IL3, P08700) IL-5 (IL5, P05113) GM-CSF (CSF2, P04141) –
Antibodies – benralizumab (Binding) (pKd 8.7) [115] mavrilimumab (Binding) (pIC50 9.9) [33] –
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IL-6 receptor family
Catalytic receptors→ Cytokine receptor family→ IL-6 receptor family
Overview: The IL-6 receptor family signal through a ternary receptor complex consisting of the cognate receptor and either the IL-6 signal transducer gp130 (IL6ST, P40189) or the oncostatin M-speciﬁc
receptor, β subunit (OSMR, Q99650), which then activates the JAK/STAT, Ras/Raf/MAPK and PI 3-kinase/PKB signalling modules. Unusually amongst the cytokine receptors, the CNTF receptor is a
glycerophosphatidylinositol-linked protein.
Nomenclature Interleukin-6 receptor Interleukin-11 receptor Interleukin-27 receptor Interleukin-31 receptor Ciliary neutrophic factor
receptor
Leukemia inhibitory
factor receptor
Oncostatin-M receptor
Subunits Interleukin-6 receptor,
α subunit
(Ligand-binding
subunit),
Interleukin-6 receptor,
β subunit (Other
subunit)
Interleukin-11 receptor,
α subunit
(Ligand-binding
subunit),
Interleukin-6 receptor,
β subunit (Other
subunit)
Interleukin-6 receptor,
β subunit (Other
subunit)
Interleukin 27 receptor,
alpha (Ligand-binding
subunit),
Interleukin-31 receptor,
α subunit
(Ligand-binding
subunit),
Oncostatin M-speciﬁc
receptor, β subunit
(Other subunit)
Leukemia inhibitory
factor receptor (Other
subunit),
Interleukin-6 receptor,
β subunit
Ciliary neurotrophic
factor receptor α subunit
(Ligand-binding subunit),
Leukemia inhibitory
factor receptor
(Ligand-binding
subunit),
Interleukin-6 receptor,
β subunit (Other
subunit)
Interleukin-6 receptor,
β subunit (Other
subunit)
Oncostatin M-speciﬁc
receptor, β subunit
(Ligand-binding subunit),
Endogenous agonists IL-6 (IL6, P05231)
(Murine NIH/3T3
ﬁbroblasts with human
IL6R exhibited a single
class of binding sites for
125I-labeled
recombinant human
interleukin-6
(125I-rhIL-6) (Kd = 440
pM, 20,000 receptors
per cell).) [185]
IL-11 (IL11, P20809) IL-27 (EBI3 IL27, Q14213
Q8NEV9)
IL-31 (IL31, Q6EBC2) CRCF1/CLCF1
heterodimer (CLCF1
CRLF1, O75462
Q9UBD9),
ciliary neurotrophic factor
(CNTF, P26441)
LIF (LIF, P15018),
cardiotrophin-1 (CTF1,
Q16619), oncostatin M
(OSM, P13725)
oncostatin M (OSM,
P13725)
Agonists – oprelvekin [11, 232] – – – – –
Antibodies vobarilizumab (Binding)
(pKd 12.7) [220],
satralizumab (Binding)
(pKd 8.9) [97],
tocilizumab (Binding)
(pKd 8.6)
– – – – – –
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Subunits
Nomenclature Interleukin-6 receptor, α subunit Interleukin-6 receptor, β subunit
Systematic nomenclature interleukin 6 receptor interleukin 6 signal transducer
Common abbreviation IL6R IL6ST
HGNC, UniProt IL6R, P08887 IL6ST, P40189
Endogenous agonists IL-6 (IL6, P05231) (IL6R) expressed stably in murine NIH/3T3 ﬁbroblasts.exhibited a
single class of binding sites for 125I-labeled recombinant human interleukin-6
(125I-rhIL-6) (Kd = 440 pM, 20,000 receptors per cell).) [185]
–
Antibodies sarilumab (Binding) (pKd 10.6–11.1) [205] –
Nomenclature Interleukin-11
receptor, α subunit
Interleukin 27
receptor, alpha
Interleukin-31
receptor, α subunit
Ciliary neurotrophic
factor receptor α subunit
Leptin receptor Leukemia inhibitory
factor receptor
Oncostatin M-speciﬁc
receptor, β subunit
HGNC, UniProt IL11RA, Q14626 IL27RA, Q6UWB1 IL31RA, Q8NI17 CNTFR, P26992 LEPR, P48357 LIFR, P42702 OSMR, Q99650
Endogenous agonists – – – – leptin (LEP, P41159)
[222] – Mouse
– –
Further reading on IL-6 receptor family
Ho LJ et al. (2015) Biological effects of interleukin-6: Clinical applications in autoimmune diseases
and cancers. Biochem. Pharmacol. 97: 16-26 [PMID:26080005]
Kang S et al. (2019) Targeting Interleukin-6 Signaling in Clinic Immunity 50: 1007-1023
Murakami M et al. (2019) Pleiotropy and Speciﬁcity: Insights from the Interleukin 6 Family of
Cytokines Immunity 50: 812-831
Rothaug M et al. (2016) The role of interleukin-6 signaling in nervous tissue. Biochim. Biophys. Acta
1863: 1218-27 [PMID:27016501]
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IL-12 receptor family
Catalytic receptors→ Cytokine receptor family→ IL-12 receptor family
Overview: IL-12 receptors are a subfamily of the IL-6 receptor family. IL12RB1 is shared between receptors for IL-12 and IL-23; the functional agonist at IL-12 receptors is a heterodimer of IL-12A/IL-12B,
while that for IL-23 receptors is a heterodimer of IL-12B/IL-23A.
Nomenclature Interleukin-12 receptor Interleukin-23 receptor
Subunits Interleukin-12 receptor, β1 subunit (Ligand-binding subunit), Interleukin-12 receptor, Interleukin 23 receptor (Ligand-binding subunit), Interleukin-12 receptor, β1 subunit
(Ligand-binding subunit)
Endogenous agonists IL-12 (IL12A IL12B, P29459 P29460) IL-23 (IL12B IL23A, P29460)
Subunits
Nomenclature Interleukin-12 receptor, β1 subunit Interleukin-12 receptor, β2 subunit Interleukin 23 receptor
HGNC, UniProt IL12RB1, P42701 IL12RB2, Q99665 IL23R, Q5VWK5
Further reading on IL-12 receptor family
Wojno EDT et al. (2019) The Immunobiology of the Interleukin-12 Family: Room for Discovery
Immunity 50: 851-870
Searchable database: http://www.guidetopharmacology.org/index.jsp IL-12 receptor family S254
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Prolactin receptor family
Catalytic receptors→ Cytokine receptor family→ Prolactin receptor family
Overview: Prolactin family receptors form homodimers in the presence of their respective ligands, associate exclusively with Jak2 and signal via Stat5.
Nomenclature Eythropoietin receptor Granulocyte colony-stimulating
factor receptor
Growth hormone receptor Prolactin receptor Thrombopoietin receptor
HGNC, UniProt EPOR, P19235 CSF3R, Q99062 GHR, P10912 PRLR, P16471 MPL, P40238
Endogenous agonists erythropoietin (EPO, P01588) [55] G-CSF (CSF3, P09919) growth hormone 1 (GH1,
P01241), growth hormone 2
(GH2, P01242)
prolactin (PRL, P01236) [58] –
Mouse, choriomammotropin
(CSH1 CSH2, P01243),
chorionic somatomammotropin
hormone-like 1 (CSHL1, Q14406)
thrombopoietin (THPO, P40225)
Agonists peginesatide [55] pegﬁlgrastim – – romiplostim
Selective agonists – – – – eltrombopag [143]
Antagonists – – pegvisomant [214] – –
Further reading on Prolactin receptor family
Cabrera-Reyes EA et al. (2017) Prolactin function and putative expression in the brain. Endocrine
57: 199-213 [PMID:28634745]
Gofﬁn V. (2017) Prolactin receptor targeting in breast and prostate cancers: New insights into an
old challenge. Pharmacol. Ther. 179: 111-126 [PMID:28549597]
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Interferon receptor family
Catalytic receptors→ Cytokine receptor family→ Interferon receptor family
Overview: The interferon receptor family includes receptors for
type I (α, β κ and ω) and type II (γ) interferons. There are at least
13 different genes encoding IFN-α subunits in a cluster on human
chromosome 9p22: α1 (IFNA1, P01562), α2 (IFNA2, P01563), α4
(IFNA4, P05014), α5 (IFNA5, P01569), α6 (IFNA6, P05013), α7
(IFNA7, P01567), α8 (IFNA8, P32881), α10 (IFNA10, P01566), α13
(IFNA13, P01562), α14 (IFNA14, P01570), α16 (IFNA16, P05015),
α17 (IFNA17, P01571) and α21 (IFNA21, P01568).
Nomenclature Interferon-α/β receptor Interferon-γ receptor
Subunits interferon α/β receptor 1 (Ligand-binding subunit), Interferon α/β receptor 2 (Other subunit) Interferon γ receptor 1 (Ligand-binding subunit), Interferon γ receptor 2 (Other subunit)
Endogenous agonists IFN-α1/13 (IFNA1 IFNA13, P01562), IFN-α10 (IFNA10, P01566), IFN-α14 (IFNA14, P01570),
IFN-α16 (IFNA16, P05015), IFN-α17 (IFNA17, P01571), IFN-α2 (IFNA2, P01563), IFN-α21
(IFNA21, P01568), IFN-α4 (IFNA4, P05014), IFN-α5 (IFNA5, P01569), IFN-α6 (IFNA6,
P05013), IFN-α7 (IFNA7, P01567), IFN-α8 (IFNA8, P32881), IFN-β (IFNB1, P01574), IFN-κ
(IFNK, Q9P0W0), IFN-ω (IFNW1, P05000)
IFN-γ (IFNG, P01579)
Selective agonists peginterferon alfa-2b [227] –
Subunits
Nomenclature interferon α/β receptor 1 Interferon α/β receptor 2 Interferon γ receptor 1 Interferon γ receptor 2
HGNC, UniProt IFNAR1, P17181 IFNAR2, P48551 IFNGR1, P15260 IFNGR2, P38484
Endogenous agonists IFN-β (IFNB1, P01574) [247] – – –
Selective agonists peginterferon alfa-2b [227] – – –
Antibodies anifrolumab (Binding) (pKd >10) [26] – – –
Further reading on Interferon receptor family
Kotenko SV et al. (2017) Contribution of type III interferons to antiviral immunity: location, loca-
tion, location. J. Biol. Chem. 292: 7295-7303 [PMID:28289095]
Lazear HM et al. (2019) Shared and Distinct Functions of Type I and Type III Interferons Immunity
50: 907-923
Ng CT et al. (2016) Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Out-
comes. Cell 164: 349-52 [PMID:26824652]
Schreiber G. (2017) The molecular basis for differential type I interferon signaling. J. Biol. Chem.
292: 7285-7294 [PMID:28289098]
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IL-10 receptor family
Catalytic receptors→ Cytokine receptor family→ IL-10 receptor family
Overview: The IL-10 family of receptors are heterodimeric combinations of family members: IL10RA/IL10RB responds to IL-10; IL20RA/IL20RB responds to IL-19, IL-20 and IL-24; IL22RA1/IL20RB
responds to IL-20 and IL-24; IL22RA1/IL10RB responds to IL-22; IFNLR1(previouly known as IL28RA)/IL10RB responds to IFN-λ1, -λ2 and -λ3 (previouly known as IL-29, IL-28A and IL-28B respectively).
Nomenclature Interleukin-10 receptor Interleukin-20 receptor Interleukin-22α1/20β
heteromer
Interleukin-22α1/10β
heteromer
Interleukin-22 receptor α2 Interferon-λ receptor 1
HGNC, UniProt – – – – IL22RA2, Q969J5 –
Subunits Interleukin 10 receptor,
α subunit (Ligand-binding
subunit),
Interleukin 10 receptor,
β subunit (Other subunit)
Interleukin 20 receptor,
β subunit (Other subunit)
Interleukin 20 receptor,
α subunit (Ligand-binding
subunit),
Interleukin 22 receptor,
α1 subunit (Ligand-binding
subunit),
Interleukin 20 receptor,
β subunit (Ligand-binding
subunit)
Interleukin 22 receptor,
α1 subunit (Ligand-binding
subunit),
Interleukin 10 receptor,
β subunit (Ligand-binding
subunit)
– Interferon-λ receptor
subunit 1 (Ligand-binding
subunit),
Interleukin 10 receptor,
β subunit (Other subunit)
Endogenous agonists IL-10 (IL10, P22301) IL-19 (IL19, Q9UHD0), IL-20
(IL20, Q9NYY1), IL-24 (IL24,
Q13007)
IL-20 (IL20, Q9NYY1), IL-24
(IL24, Q13007)
IL-22 (IL22, Q9GZX6) – IFN-λ1 (IFNL1, Q8IU54),
IFN-λ2 (IFNL2, Q8IZJ0),
IFN-λ3 (IFNL3, Q8IZI9)
Comments – – – – Soluble decoy receptor that
binds IL-22 (IL22, Q9GZX6)
as a monomer.
–
Subunits
Nomenclature Interleukin 10 receptor,
α subunit
Interleukin 10 receptor,
β subunit
Interleukin 20 receptor,
α subunit
Interleukin 20 receptor,
β subunit
Interleukin 22 receptor,
α1 subunit
Interferon-λ receptor
subunit 1
HGNC, UniProt IL10RA, Q13651 IL10RB, Q08334 IL20RA, Q9UHF4 IL20RB, Q6UXL0 IL22RA1, Q8N6P7 IFNLR1, Q8IU57
Further reading on IL-10 receptor family
Felix J et al. (2017) Mechanisms of immunomodulation by mammalian and viral decoy receptors:
insights from structures. Nat. Rev. Immunol. 17: 112-129 [PMID:28028310]
Ouyang W et al. (2019) IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical
Translation Immunity 50: 871-891
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Immunoglobulin-like family of IL-1 receptors
Catalytic receptors→ Cytokine receptor family→ Immunoglobulin-like family of IL-1 receptors
Overview: The immunoglobulin-like family of IL-1 receptors are heterodimeric receptors made up of a cognate receptor subunit and an IL-1 receptor accessory protein, IL1RAP (Q9NPH3, also known as
C3orf13, IL-1RAcP, IL1R3). They are characterised by extracellular immunoglobulin-like domains and an intracellular Toll/Interleukin-1R (TIR) domain.
Nomenclature Interleukin-1 receptor, type I Interleukin-33 receptor Interleukin-36 receptor Interleukin-1 receptor, type II Interleukin-18 receptor
Subunits
IL-1 receptor accessory protein
(Other subunit)
Interleukin 1 receptor, type I
(Ligand-binding subunit),
IL-1 receptor accessory protein
(Other subunit)
Interleukin-1 receptor-like 1
(Ligand-binding subunit),
IL-1 receptor accessory protein
(Other subunit)
Interleukin-1 receptor-like 2
(Ligand-binding subunit),
IL-1 receptor accessory protein
(Other subunit)
Interleukin 1 receptor, type II
(Ligand-binding subunit),
IL-18 receptor accessory protein
(Other subunit)
Interleukin-18 receptor 1
(Ligand-binding subunit),
Inhibitors anakinra (pKd 7.8) [49] – – – –
Endogenous agonists IL-1α (IL1A, P01583), IL-1β (IL1B,
P01584)
IL-33 (IL33, O95760) IL-36α (IL36A, Q9UHA7), IL-36β
(IL36B, Q9NZH7), IL-36γ (IL36G,
Q9NZH8)
– IL-18 (IL18, Q14116), IL-37 (IL37,
Q9NZH6)
Endogenous antagonists IL-1 receptor antagonist (IL1RN,
P18510)
– IL-36 receptor antagonist (IL36RN,
Q9UBH0)
– –
Selective antagonists AF12198 [1] – – – –
Comments – – IL-36 receptor antagonist (IL36RN,
Q9UBH0) is a highly speciﬁc
antagonist of the response to
IL-36γ (IL36G, Q9NZH8).
Decoy receptor that binds IL-1α
(IL1A, P01583), IL-1β (IL1B,
P01584) and
IL-1 receptor antagonist (IL1RN,
P18510).
–
Subunits
Nomenclature Interleukin 1 receptor, type I Interleukin 1 receptor, type II Interleukin-1 receptor-like 1 Interleukin-1 receptor-like 2 Interleukin-18 receptor 1
HGNC, UniProt IL1R1, P14778 IL1R2, P27930 IL1RL1, Q01638 IL1RL2, Q9HB29 IL18R1, Q13478
Further reading on Immunoglobulin-like family of IL-1 receptors
Afonina IS et al. (2015) Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a
Common Theme. Immunity 42: 991-1004 [PMID:26084020]
Mantovani A et al. (2019) Interleukin-1 and Related Cytokines in the Regulation of Inﬂammation
and Immunity Immunity 50: 778-795
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IL-17 receptor family
Catalytic receptors→ Cytokine receptor family→ IL-17 receptor family
Overview: The IL17 cytokine family consists of six ligands (IL-17A-F), which signal through ﬁve receptors (IL-17RA-E).
Nomenclature Interleukin-17 receptor Interleukin-25 receptor Interleukin-17C receptor
Subunits Interleukin 17 receptor A (Ligand-binding subunit),
interleukin 17 receptor C (Other subunit)
Interleukin 17 receptor B (Ligand-binding subunit),
Interleukin 17 receptor A (Other subunit) Interleukin 17 receptor A (Other subunit)
Interleukin 17 receptor E (Ligand-binding subunit),
Endogenous agonists IL-17A (IL17A, Q16552), IL-17A/IL-17F (IL17A IL17F,
Q16552 Q96PD4), IL-17F (IL17F, Q96PD4)
IL-17B (IL17B, Q9UHF5), IL-25 (IL25, Q9H293) IL-17C (IL17C, Q9P0M4)
Subunits
Nomenclature Interleukin 17 receptor A Interleukin 17 receptor B interleukin 17 receptor C Interleukin-17 receptor D Interleukin 17 receptor E
HGNC, UniProt IL17RA, Q96F46 IL17RB, Q9NRM6 IL17RC, Q8NAC3 IL17RD, Q8NFM7 IL17RE, Q8NFR9
Antibodies brodalumab (Binding) (pKd 9.2)
[213]
– – – –
Comments – – – The endogenous agonist for this
receptor is unknown.
–
Further reading on IL-17 receptor family
Beringer A et al. (2016) IL-17 in Chronic Inﬂammation: From Discovery to Targeting. Trends Mol
Med 22: 230-241 [PMID:26837266]
Lubberts E. (2015) The IL-23-IL-17 axis in inﬂammatory arthritis. Nat Rev Rheumatol 11: 415-29
[PMID:25907700]
McGeachy MJ et al. (2019) The IL-17 Family of Cytokines in Health and Disease Immunity 50:
892-906
GDNF receptor family
Catalytic receptors→ GDNF receptor family
Overview: GDNF family receptors (provisional nomenclature) are extrinsic tyrosine kinase receptors. Ligand binding to the extracellular domain of the glycosylphosphatidylinositol-linked cell-surface
receptors (tabulated below) activates a transmembrane tyrosine kinase enzyme, RET (see Receptor Tyrosine Kinases). The endogenous ligands are typically dimeric, linked through disulphide bridges: glial
cell-derived neurotrophic factor GDNF (GDNF, P39905) (211 aa); neurturin (NRTN, Q99748) (197 aa); artemin (ARTN, Q5T4W7) (237 aa) and persephin (PSPN, O60542) (PSPN, 156 aa).
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Nomenclature GDNF family receptor α1 GDNF family receptor α2 GDNF family receptor α3 GDNF family receptor α4
Common abbreviation GFRα1 GFRα2 GFRα3 GFRα4
HGNC, UniProt GFRA1, P56159 GFRA2, O00451 GFRA3, O60609 GFRA4, Q9GZZ7
Potency order GDNF (GDNF, P39905) > neurturin (NRTN,
Q99748) > artemin (ARTN, Q5T4W7)
neurturin (NRTN, Q99748) > GDNF
(GDNF, P39905)
artemin (ARTN, Q5T4W7) persephin (PSPN, O60542)
Labelled ligands [125I]GDNF (rat) (pKd 10.2–11.5) [113,
215]
– – –
Comments: Inhibitors of other receptor tyrosine kinases, such as semaxanib, which inhibits VEGF receptor function, may also inhibit Ret function [157]. Mutations of RET and GDNF genes may be
involved in Hirschsprung’s disease, which is characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction.
Further reading on GDNF receptor family
Allen SJ et al. (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharma-
col. Ther. 138: 155-75 [PMID:23348013]
Ibáñez CF et al. (2017) Biology of GDNF and its receptors - Relevance for disorders of the central
nervous system. Neurobiol. Dis. 97: 80-89 [PMID:26829643]
Merighi A. (2016) Targeting the glial-derived neurotrophic factor and related molecules for control-
ling normal and pathologic pain. Expert Opin. Ther. Targets 20: 193-208 [PMID:26863504]
Integrins
Catalytic receptors→ Integrins
Overview: Integrins are unusual signalling proteins that func-
tion to signal both from the extracellular environment into the
cell, but also from the cytoplasm to the external of the cell. The in-
tracellular signalling cascades associated with integrin activation
focus on protein kinase activities, such as focal adhesion kinase
and Src. Based on this association between extracellular signals
and intracellular protein kinase activity, we have chosen to in-
clude integrins in the ’Catalytic receptors’ section of the database
until more stringent criteria from NC-IUPHAR allows precise def-
inition of their classiﬁcation.
Integrins are heterodimeric entities, composed of α and β
subunits, each 1TM proteins, which bind components of the
extracellular matrix or counter-receptors expressed on other cells.
One class of integrin contains an inserted domain (I) in its α sub-
unit, and if present (in α1, α2, α10, α11, αD, αE, αL, αM and αX),
this I domain contains the ligand binding site. All β subunits pos-
sess a similar I-like domain, which has the capacity to bind ligand,
often recognising the RGD motif. The presence of an α subunit I
domain precludes ligand binding through the β subunit. Integrins
provide a link between ligand and the actin cytoskeleton (through
typically short intracellular domains). Integrins bind several diva-
lent cations, including a Mg2+ ion in the I or I-like domain that
is essential for ligand binding. Other cation binding sites may
regulate integrin activity or stabilise the 3D structure. Integrins
regulate the activity of particular protein kinases, including focal
adhesion kinase and integrin-linked kinase. Cellular activation
regulates integrin ligand afﬁnity via inside-out signalling and lig-
and binding to integrins can regulate cellular activity via outside-
in signalling.
Several drugs that target integrins are in clinical use including: (1)
abciximab (αIIbβ3) for short term prevention of coronary throm-
bosis, (2) vedolizumab (α4β7) to reduce gastrointestinal inﬂamma-
tion, and (3) natalizumab (α4β1) in some cases of severe multiple
sclerosis.
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Nomenclature integrin α1β1 integrin α2β1 integrin αIIbβ3 integrin α4β1
Subunits integrin, beta 1 subunit
(ﬁbronectin receptor, beta
polypeptide, antigen CD29
includes MDF2, MSK12),
integrin, alpha 1 subunit
integrin, beta 1 subunit
(ﬁbronectin receptor, beta
polypeptide, antigen CD29
includes MDF2, MSK12),
integrin, alpha 2 subunit
(CD49B, alpha 2 subunit of
VLA-2 receptor)
integrin, beta 3 subunit
(platelet glycoprotein IIIa,
antigen CD61), integrin, alpha IIb subunit
(platelet glycoprotein IIb of IIb/IIIa complex,
antigen CD41)
integrin, beta 1 subunit
(ﬁbronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12),
integrin, alpha 4 subunit (antigen CD49D,
alpha 4 subunit of VLA-4 receptor)
Ligands collagen, laminin collagen, laminin, thrombospondin ﬁbrinogen (FGA FGB FGG, P02671 P02675
P02679), ﬁbronectin (FN1, P02751),
von Willebrand factor (VWF, P04275),
vitronectin (VTN, P04004), thrombospondin
ﬁbronectin (FN1, P02751),
vascular cell adhesion protein 1 (VCAM1,
P19320), osteopontin (SPP1, P10451),
thrombospondin
Inhibitors obtustatin (pIC50 9.1) [142] TCI15 (pIC50 7.9) [154] tiroﬁban (pIC50 9.4) [216], G4120 (pKi 8.4)
[149, 242], GR 144053 (pIC50 7.4) [51],
eptiﬁbatide (pIC50 6.2–6.8) [190]
BIO1211 (pIC50 8.3–9) [130], TCS2314
Antibodies – – abciximab (Binding) [35] natalizumab (Inhibition) [166]
Comments – – – LDV-FITC is used as a probe at this receptor.
Nomenclature integrin α4β7 integrin α5β1 integrin α6β1 integrin α10β1
Subunits integrin, alpha 4 subunit
(antigen CD49D, alpha 4
subunit of VLA-4 receptor),
integrin, beta 7 subunit
integrin, beta 1 subunit
(ﬁbronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12),
integrin, alpha 5 subunit (ﬁbronectin
receptor, alpha polypeptide)
integrin, beta 1 subunit (ﬁbronectin receptor,
beta polypeptide, antigen CD29 includes
MDF2, MSK12), integrin, alpha 6 subunit
integrin, beta 1 subunit
(ﬁbronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12),
integrin, alpha 10 subunit
Ligands – ﬁbronectin (FN1, P02751) laminin collagen
Antibodies vedolizumab (Antagonist) (pIC50 8.3) [179] volociximab (Binding) (pKd 9.5) [12, 13] – –
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Nomenclature integrin α11β1 integrin αEβ7 integrin αLβ2 integrin αVβ3
Subunits integrin, beta 1 subunit
(ﬁbronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12),
integrin, alpha 11 subunit
integrin, alpha E subunit
(antigen CD103, human mucosal
lymphocyte antigen 1; alpha polypeptide),
integrin, beta 7 subunit
integrin, beta 2 subunit
(complement component 3 receptor
3 and 4 subunit),
integrin, alpha L subunit (antigen
CD11A (p180), lymphocyte
function-associated antigen 1; alpha
polypeptide)
integrin, beta 3 subunit
(platelet glycoprotein IIIa, antigen CD61),
integrin, alpha V subunit
Ligands collagen E-cadherin ICAM-1 (ICAM1, P05362), ICAM-2 (ICAM2,
P13598)
vitronectin (VTN, P04004), ﬁbronectin (FN1,
P02751), ﬁbrinogen (FGA FGB FGG, P02671
P02675 P02679), osteopontin (SPP1, P10451),
von Willebrand factor (VWF, P04275),
thrombospondin, tenascin
Activators – – – TP508 (pKd 7.9) [46]
Inhibitors – – A286982 (pIC50 7.4–7.5) [133] echistatin (pIC50 11.7) [124], P11 (pIC50 11.6)
[124], cilengitide (pIC50 8.5) [72]
Antibodies – – – etaracizumab (Binding) (pKd 6.3) [237]
Subunits
Nomenclature integrin, alpha 1 subunit integrin, alpha 2 subunit
(CD49B, alpha 2 subunit of
VLA-2 receptor)
integrin, alpha IIb subunit
(platelet glycoprotein IIb of
IIb/IIIa complex, antigen
CD41)
integrin, alpha 3 subunit
(antigen CD49C, alpha 3
subunit of VLA-3 receptor)
integrin, alpha 4 subunit
(antigen CD49D, alpha 4
subunit of VLA-4 receptor)
integrin, alpha 5 subunit
(ﬁbronectin receptor,
alpha polypeptide)
HGNC, UniProt ITGA1, P56199 ITGA2, P08514 ITGA2B, P17301 ITGA3, P26006 ITGA4, P13612 ITGA5, P08648
Ligands – – – peptide ligand 2 (Binding)
(pIC50 7.2) [241]
– –
Antibodies – – – – natalizumab (Inhibition)
[166]
volociximab (Binding) (pKd
9.5) [12, 13]
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Nomenclature integrin, alpha 6 subunit integrin, alpha 7 subunit integrin, alpha 8 subunit integrin, alpha 9 subunit integrin, alpha 10 subunit integrin, alpha 11 subunit integrin, alpha D subunit
HGNC, UniProt ITGA6, P23229 ITGA7, Q13683 ITGA8, P53708 ITGA9, Q13797 ITGA10, O75578 ITGA11, Q9UKX5 ITGAD, Q13349
Nomenclature integrin, alpha E subunit
(antigen CD103, human
mucosal lymphocyte antigen
1; alpha polypeptide)
integrin, alpha L subunit
(antigen CD11A (p180),
lymphocyte function-
associated antigen 1; alpha
polypeptide)
integrin, alpha M subunit
(complement component
3 receptor 3 subunit)
integrin, alpha V subunit integrin, alpha X subunit
(complement component 3
receptor 4 subunit)
integrin, beta 1 subunit
(ﬁbronectin receptor, beta
polypeptide, antigen CD29
includes MDF2, MSK12)
HGNC, UniProt ITGAE, P38570 ITGAL, P20701 ITGAM, P11215 ITGAV, P06756 ITGAX, P20702 ITGB1, P05556
Antagonists – liﬁtegrast (Inhibition) [18,
249]
– MK-0429 (pIC50 7.1) [95] – –
Antibodies – efalizumab (Binding) (pKd
11.4) [100]
– – – –
Nomenclature integrin, beta 2 subunit
(complement component
3 receptor 3 and 4
subunit)
integrin, beta 3 subunit
(platelet glycoprotein IIIa,
antigen CD61)
integrin, beta 4 subunit integrin, beta 5 subunit integrin, beta 6 subunit integrin, beta 7 subunit integrin, beta 8 subunit
HGNC, UniProt ITGB2, P05107 ITGB3, P05106 ITGB4, P16144 ITGB5, P18084 ITGB6, P18564 ITGB7, P26010 ITGB8, P26012
Comments: Integrin ligands
Collagen is the most abundant protein in metazoa, rich in
glycine and proline residues, made up of cross-linked triple he-
lical structures, generated primarily by ﬁbroblasts. Extensive
post-translational processing is conducted by prolyl and lysyl
hydroxylases, as well as transglutaminases. Over 40 genes
for collagen-α subunits have been identiﬁed in the human
genome. The collagen-binding integrins α1β1, α2β1, α10β1 and
α11β1 recognise a range of triple-helical peptide motifs including
GFOGER (O = hydroxyproline), a synthetic peptide derived from
the primary sequence of collagen I (COL1A1 (COL1A1, P02452))
and collagen II (COL2A1 (COL2A1, P02458)).
Laminin is an extracellular glycoprotein composed of α, β and
γ chains, for which ﬁve, four and three genes, respectively, are
identiﬁed in the human genome. It binds to α1β1, α2β1, α3,β1,
α7β1 and α6β4 integrins10.
ﬁbrinogen (FGA FGB FGG, P02671 P02675 P02679) is a gly-
cosylated hexamer composed of two α (FGA, P02671), two β (FGB,
P02675) and two γ (FGG, P02679,) subunits, linked by disulphide
bridges. It is found in plasma and alpha granules of platelets. It
forms cross-links between activated platelets mediating aggrega-
tion by binding αIIbβ3; proteolysis by thrombin cleaves short pep-
tides termed ﬁbrinopeptides to generate ﬁbrin, which polymerises
as part of the blood coagulation cascade.
ﬁbronectin (FN1, P02751) is a disulphide-linked homodimer
found as two major forms; a soluble dimeric form found in the
plasma and a tissue version that is polymeric, which is secreted
into the extracellular matrix by ﬁbroblasts. Splice variation of the
gene product (FN1, P02751) generates multiple isoforms.
vitronectin (VTN, P04004) is a serum glycoprotein and extra-
cellular matrix protein which is found either as a monomer or,
following proteolysis, a disulphide -linked dimer.
osteopontin (SPP1, P10451) forms an integral part of the
mineralized matrix in bone, where it undergoes extensive post-
translation processing, including proteolysis and phosphoryla-
tion.
von Willebrand factor (VWF, P04275) is a glycoprotein syn-
thesised in vascular endothelial cells as a disulphide-linked ho-
modimer, but multimerises further in plasma and is deposited on
vessel wall collagen as a high molecular weight multimer. It is
responsible for capturing platelets under arterial shear ﬂow (via
GPIb) and in thrombus propagation (via integrin αIIbβ3).
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Further reading on Integrins
Clemetson KJ. (2017) The origins of major platelet receptor nomenclature. Platelets 28: 40-42
[PMID:27715379]
Emsley J et al. (2000) Structural basis of collagen recognition by integrin alpha2beta1. Cell 101:
47-56 [PMID:10778855]
Hamidi H et al. (2016) The complexity of integrins in cancer and new scopes for therapeutic target-
ing. Br. J. Cancer 115: 1017-1023 [PMID:27685444]
Horton ER et al. (2016) The integrin adhesome network at a glance. J. Cell. Sci. 129: 4159-4163
[PMID:27799358]
Ley K et al. (2016) Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev
Drug Discov 15: 173-83 [PMID:26822833]
Manninen A et al. (2017) A proteomics view on integrin-mediated adhesions. Proteomics 17:
[PMID:27723259]
Raab-Westphal S et al. (2017) Integrins as Therapeutic Targets: Successes andCancers. Cancers (Basel)
9: [PMID:28832494]
Pattern recognition receptors
Catalytic receptors→ Pattern recognition receptors
Overview: Pattern Recognition Receptors (PRRs, [208]) (nomen-
clature as agreed by NC-IUPHAR sub-committee on Pat-
tern Recognition Receptors, [22]) participate in the innate
immune response to microbial agents, the stimulation of which
leads to activation of intracellular enzymes and regulation of
gene transcription. PRRs express multiple leucine-rich regions
to bind a range of microbially-derived ligands, termed PAMPs
or pathogen-associated molecular patterns or endogenous lig-
ands, termed DAMPS or damage-associated molecular patterns.
These include peptides, carbohydrates, peptidoglycans, lipopro-
teins, lipopolysaccharides, and nucleic acids. PRRs include both
cell-surface and intracellular proteins. PRRs may be divided
into signalling-associated members, identiﬁed here, and endo-
cytic members, the function of which appears to be to recognise
particular microbial motifs for subsequent cell attachment, inter-
nalisation and destruction. Some are involved in inﬂammasome
formation, and modulation of IL-1β cleavage and secretion, and
others in the initiation of the type I interferon response.
PRRs included in the Guide To PHARMACOLOGY are:
Catalytic PRRs (see links below this overview)
Toll-like receptors (TLRs)
Nucleotide-binding oligomerization domain, leucine-rich repeat
containing receptors (NLRs, also known as NOD (Nucleotide
oligomerisation domain)-like receptors)
RIG-I-like receptors (RLRs)
Caspase 4 and caspase 5
Non-catalytic PRRs
Absent in melanoma (AIM)-like receptors (ALRs)
C-type lectin-like receptors (CLRs)
Other pattern recognition receptors
Advanced glycosylation end-product speciﬁc receptor (RAGE)
Toll-like receptor family
Catalytic receptors→ Pattern recognition receptors→ Toll-like receptor family
Overview: Members of the toll-like family of receptors (nomen-
clature recommended by the NC-IUPHAR subcommittee on pat-
tern recognition receptors, [22]) share signiﬁcant homology with
the interleukin-1 receptor family and appear to require dimer-
ization either as homo- or heterodimers for functional activity.
Heterodimerization appears to inﬂuence the potency of ligand
binding substantially (e.g. TLR1/2 and TLR2/6, [209, 210]). TLR1,
TLR2, TLR4, TLR5, TLR6 and TLR11 are cell-surface proteins,
while other members are associated with intracellular organelles,
signalling through the MyD88-dependent pathways (with the
exception of TLR3). As well as responding to exogenous infectious
agents, it has been suggested that selected members of the family
may be activated by endogenous ligands, such as hsp60 (HSPD1,
P10809) [167].
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Nomenclature TLR1 TLR2 TLR3 TLR4 TLR5
HGNC, UniProt TLR1, Q15399 TLR2, O60603 TLR3, O15455 TLR4, O00206 TLR5, O60602
Agonists – compound 13 [96], peptidoglycan
[193, 244]
poly(I:C) [3] LPS [178], paclitaxel [107] –
Mouse
ﬂagellin [84]
Selective antagonists – – – resatorvid [98] –
Comments Functions as a heterodimer with
TLR2 in detection of triacylated
lipoproteins. Activated by the
synthetic analogue Pam3CSK4.
Functions as a heterodimer with
either TLR1 or TLR6 in the
detection of triacylated and
diacylated lipopeptides
respectively. TLR1/2 and 2/6
heterodimers can be activated by
the synthetic lipopeptides
Pam3CSK4 and Pam2CSK4
respectively. There is some debate
in the ﬁeld as to whether or not
peptidoglycan is a direct agonist
of TLR2, or whether the early
studies reporting this contained
contaminating lipoproteins.
Involved in endosomal detection
of dsRNA; pro-inﬂammatory.
Eritoran (E5564) is a lipid A
analogue, which has been
described as a TLR4 antagonist
[99]. TLR4 signals in conjunction
with the co-factor MD-2 (LY96).
Involved in the detection of
bacterial ﬂagellin;
pro-inﬂammatory.
Nomenclature TLR6 TLR7 TLR8 TLR9 TLR10 TLR11
HGNC, UniProt TLR6, Q9Y2C9 TLR7, Q9NYK1 TLR8, Q9NR97 TLR9, Q9NR96 TLR10, Q9BXR5 –
Agonists – resiquimod [88, 104, 121],
imiquimod [121], loxoribine
[86]
resiquimod [88, 104, 121] – – –
Antagonists – hydroxychloroquine (pIC50
5.6) [120]
– hydroxychloroquine (pIC50
7.1) [120]
– –
Comments Functions as a heterodimer
with TLR2. Involved in the
pro-inﬂammatory response
to diacylated bacterial
lipopeptides.
Activated by
imidazoquinoline derivatives
and RNA
oligoribonucleotides.
Involved in endosomal
detection of ssRNA;
pro-inﬂammatory.
Activated by
imidazoquinoline derivatives
and RNA
oligoribonucleotides.
Endosomal detection of
ssRNA; pro-inﬂammatory.
Toll-like receptor 9 interacts
with unmethylated CpG
dinucleotides from bacterial
DNA [89]. Activated by CpG
rich DNA sequences;
pro-inﬂammatory.
TLR10 is the only
pattern-recognition receptor
without known ligand
speciﬁcity and biological
function. Evidence suggests
it plays a modulatory role
with predominantly
inhibitory
(anti-inﬂammatory) actions
[173]. Murine TLR10 has a
retroviral insertion that
makes it non-functional.
Found in mouse
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Further reading on Toll-like receptor family
Anthoney N et al. (2018) Toll and Toll-like receptor signalling in development. Development 145:
[PMID:29695493]
Bryant CE et al. (2015) International Union of Basic and Clinical Pharmacology. XCVI. Pattern
recognition receptors in health and disease. Pharmacol. Rev. 67: 462-504 [PMID:25829385]
Franz KM et al. (2017) Innate Immune Receptors as Competitive Determinants of Cell Fate. Mol.
Cell 66: 750-760 [PMID:28622520]
Joosten LA et al. (2016) Toll-like receptors and chronic inﬂammation in rheumatic diseases: new
developments. Nat Rev Rheumatol 12: 344-57 [PMID:27170508]
Nunes KP et al. (2018) Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the
toll for hypertension? Br. J. Pharmacol. [PMID:29981161]
Zhang Z et al. (2017) Toward a structural understanding of nucleic acid-sensing Toll-like receptors
in the innate immune system. FEBS Lett. 591: 3167-3181 [PMID:28686285]
NOD-like receptor family
Catalytic receptors→ Pattern recognition receptors→ NOD-like receptor family
Overview: The nucleotide-binding oligomerization domain,
leucine-rich repeat (NLR) family of receptors (nomenclature rec-
ommended by the NC-IUPHAR subcommittee on pattern recog-
nition receptors [22]) share a common domain organisation. This
consists of an N-terminal effector domain, a central nucleotide-
binding and oligomerization domain (NOD; also referred to as a
NACHTdomain), andC-terminal leucine-rich repeats (LRR) which
have regulatory and ligand recognition functions. The type of ef-
fector domain has resulted in the division of NLR family members
into two major sub-families, NLRC and NLRP, along with three
smaller sub-families NLRA, NLRB and NLRX [212]. NLRC mem-
bers express an N-terminal caspase recruitment domain (CARD)
and NLRP members an N-terminal Pyrin domain (PYD).
Upon activation the NLRC family members NOD1 (NLRC1) and
NOD2 (NLRC2) recruit a serine/threonine kinase RIPK2 (recep-
tor interacting serine/threonine kinase 2, O43353, also known
as CARD3, CARDIAK, RICK, RIP2) leading to signalling through
NFκB and MAP kinase. Activation of NLRC4 (previously known
as IPAF) and members of the NLRP3 family, including NLRP1 and
NLRP3, leads to formation of a large multiprotein complex known
as the inﬂammasome. In addition to NLR proteins other key
members of the inﬂammasome include the adaptor protein ASC
(apoptosis-associated speck-like protein containing a CARD, also
known as PYCARD, CARD5, TMS1, Q9ULZ3) and inﬂammatory
caspases. The inﬂammasome activates the pro-inﬂammatory cy-
tokines IL-1β (IL1B, P01584) and IL-18 (IL18, Q14116) [22, 41].
Nomenclature nucleotide binding
oligomerization domain
containing 1
nucleotide binding
oligomerization domain
containing 2
NLRC3 NLRC4 NLRC5 NLRX1 CIITA
Common abbreviation NOD1 NOD2 – – – – –
HGNC, UniProt NOD1, Q9Y239 NOD2, Q9HC29 NLRC3, Q7RTR2 NLRC4, Q9NPP4 NLRC5, Q86WI3 NLRX1, Q86UT6 CIITA, P33076
Agonists meso-DAP muramyl dipeptide – – – – –
Comments – NOD2 has also been
reported to be
activated by ssRNA
[187] although this has
not been widely
reproduced.
– NLRC4 forms an
inﬂammasome with the
NAIP proteins following
recognition of bacterial
ﬂagellin and type III
secretion system rod
proteins by the NAIPs.
– – –
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Nomenclature NLRP1 NLRP2 NLRP3
HGNC, UniProt NLRP1, Q9C000 NLRP2, Q9NX02 NLRP3, Q96P20
Inhibitors – – MCC950 (pIC50 >8) [34]
Agonists muramyl dipeptide – –
Comments NLRP1 has 3 murine orthologues which lack the N-terminal Pyrin
domain. Murine NLRP1b (ENSMUSG00000070390) is the best
characterised, responding to Anthrax Lethal Toxin.
Along with NLRP7, NLRP2 is the product of a
primate-speciﬁc gene duplication.
NLRP3 has been shown to be activated following disruption of
cellular haemostasis by a wide-variety of exogenous and
endogenous molecules. The identity of the precise agonist that
interacts with NLRP3 remains enigmatic. Efﬂux of potassium
ions appears to be a common event for NLRP3 activating
molecules. In addition to MCC950 [34] other small molecules
including CY-09 [102], β-hydroxybutyrate [245], and various
boron containing compounds [8] modulate NLRP3.
Nomenclature NLRP4 NLRP5 NLRP6 NLRP7 NLRP8 NLRP9
HGNC, UniProt NLRP4, Q96MN2 NLRP5, P59047 NLRP6, P59044 NLRP7, Q8WX94 NLRP8, Q86W28 NLRP9, Q7RTR0
Comments Expanded in the mouse
resulting in 7 orthologues.
– – Absent in mouse. Along with
NLRP2 the product of a
primate-speciﬁc gene duplication.
Absent in mouse This receptor has three
murine orthologues.
Nomenclature NLRP10 NLRP11 NLRP12 NLRP13 NLRP14
HGNC, UniProt NLRP10, Q86W26 NLRP11, P59045 NLRP12, P59046 NLRP13, Q86W25 NLRP14, Q86W24
Comments NLRP10 lacks the LRR region. Absent in mouse – Absent in mouse –
Comments: NLRP3 has also been reported to respond to host-
derived products, known as danger-associated molecular patterns,
or DAMPs, including uric acid [147], ATP, L-glucose, hyaluronan
and amyloid β (APP, P05067) [191].
Loss-of-function mutations of NLRP3 are associated with cold au-
toinﬂammatory and Muckle-Wells syndromes.
This family also includes NLR family, apoptosis inhibitory protein
(NAIP, Q13075) which can be found in the ’Inhibitors of
apoptosis (IAP) protein family’ in the Other protein targets sec-
tion of the Guide.
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Further reading on NOD-like receptor family
Broz P et al. (2016) Inﬂammasomes: mechanism of assembly, regulation and signalling. Nat. Rev.
Immunol. 16: 407-20 [PMID:27291964]
Bryant CE et al. (2015) International Union of Basic and Clinical Pharmacology. XCVI. Pattern
recognition receptors in health and disease. Pharmacol. Rev. 67: 462-504 [PMID:25829385]
Keestra-Gounder AM et al. (2017) NOD1 and NOD2: Beyond Peptidoglycan Sensing. Trends Im-
munol. 38: 758-767 [PMID:28823510]
Lei-Leston AC et al. (2017) Epithelial Cell Inﬂammasomes in Intestinal Immunity and Inﬂamma-
tion. Front Immunol 8: 1168 [PMID:28979266]
Man SM. (2018) Inﬂammasomes in the gastrointestinal tract: infection, cancer and gut microbiota
homeostasis. Nat Rev Gastroenterol Hepatol 15: 721-737 [PMID:30185915]
Mukherjee T et al. (2018) NOD1 and NOD2 in inﬂammation, immunity and disease. Arch. Biochem.
Biophys. [PMID:30578751]
Nielsen AE et al. (2017) Synthetic agonists of NOD-like, RIG-I-like, and C-type lectin receptors for
probing the inﬂammatory immune response. Future Med Chem 9: 1345-1360 [PMID:28776416]
RIG-I-like receptor family
Catalytic receptors→ Pattern recognition receptors→ RIG-I-like receptor family
Overview: There are three human RIG-I-like receptors (RLRs) which are cytoplasmic pattern recognition receptors (PRRs) of the innate immune system. They detect non-self cytosolic double-stranded
RNA species and and 5’-triphosphate single-stranded RNA from various sources and are essential for inducing production of type I interferons, such as IFNβ, type III interferons, and other anti-pathogenic
effectors [21, 22]. They function as RNA helicases (EC 3.6.4.13) using the energy from ATP hydrolysis to unwind RNA.
Nomenclature DExD/H-box helicase 58 interferon induced with helicase C domain 1 DExH-box helicase 58
Common abbreviation RIG-1 MDA5 LGP2
HGNC, UniProt DDX58, O95786 IFIH1, Q9BYX4 DHX58, Q96C10
Further reading on RIG-I-like receptor family
Chow KT et al. (2018) RIG-I and Other RNA Sensors in Antiviral Immunity. Annu. Rev. Immunol.
36: 667-694 [PMID:29677479]
Kato H et al. (2015) RIG-I-like receptors and autoimmune diseases. Curr. Opin. Immunol. 37: 40-5
[PMID:26530735]
Lässig C et al. (2017) Discrimination of cytosolic self and non-self RNA by RIG-I-like receptors. J.
Biol. Chem. 292: 9000-9009 [PMID:28411239]
Ma Z et al. (2018) Innate Sensing of DNA Virus Genomes. Annu Rev Virol 5: 341-362
[PMID:30265633]
Yong HY et al. (2018) RIG-I-Like Receptors as Novel Targets for Pan-Antivirals and Vaccine Adjuvants
Against Emerging and Re-Emerging Viral Infections. Front Immunol 9: 1379 [PMID:29973930]
Further reading on Pattern recognition receptors
Broz P et al. (2016) Inﬂammasomes: mechanism of assembly, regulation and signalling. Nat. Rev.
Immunol. 16: 407-20 [PMID:27291964]
Bryant CE et al. (2015) Advances in Toll-like receptor biology: Modes of activation by diverse stim-
uli. Crit. Rev. Biochem. Mol. Biol. 50: 359-79 [PMID:25857820]
Feerick CL et al. (2017) Understanding the regulation of pattern recognition receptors in inﬂamma-
tory diseases - a ’Nod’ in the right direction. Immunology 150: 237-247 [PMID:27706808]
Rathinam VA et al. (2016) Inﬂammasome Complexes: Emerging Mechanisms and Effector Func-
tions. Cell 165: 792-800 [PMID:27153493]
Unterholzner L. (2013) The interferon response to intracellular DNA: why so many receptors? Im-
munobiology 218: 1312-21 [PMID:23962476]
Yin Q et al. (2015) Structural biology of innate immunity. Annu. Rev. Immunol. 33: 393-416
[PMID:25622194]
Searchable database: http://www.guidetopharmacology.org/index.jsp RIG-I-like receptor family S268
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14751/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology (2019) 176, S247–S296
Receptor guanylyl cyclase (RGC) family
Catalytic receptors→ Receptor guanylyl cyclase (RGC) family
Overview: The mammalian genome encodes transmembrane and soluble receptor guanylyl cyclases, both of which have enzyme activities which convert guanosine-5’-triphosphate to the intracellular
second messenger cyclic guanosine-3’,5’-monophosphate (cyclic GMP).
Transmembrane guanylyl cyclases
Catalytic receptors→ Receptor guanylyl cyclase (RGC) family→ Transmembrane guanylyl cyclases
Overview: Transmembrane guanylyl cyclases are homodimeric
receptors activated by a diverse range of endogenous ligands.
GC-A, GC-B and GC-C are expressed predominantly in the car-
diovascular system, skeletal system and intestinal epithelium,
respectively. GC-D and GC-G are found in the olfactory neuro-
pepithelium and Grüeneberg ganglion of rodents, respectively.
GC-E and GC-F are expressed in retinal photoreceptors. Family
members have conserved ligand-binding, catalytic (guanylyl cy-
clase) and regulatory domains with the exception of NPR-C which
has an extracellular binding domain homologous to that of other
NPRs, but with a truncated intracellular domain which appears to
couple, via the Gi/o family of G proteins, to activation of phospho-
lipase C, inwardly-rectifying potassium channels and inhibition of
adenylyl cyclase activity [161].
Nomenclature Guanylyl cyclase-A Guanylyl cyclase-B Guanylyl cyclase-C natriuretic peptide receptor 3
Common abbreviation GC-A GC-B GC-C NPR-C
HGNC, UniProt NPR1, P16066 NPR2, P20594 GUCY2C, P25092 NPR3, P17342
Potency order atrial natriuretic peptide (NPPA, P01160) ≥
brain natriuretic peptide (NPPB, P16860)
 C-type natriuretic peptide (NPPC,
P23582) [207]
C-type natriuretic peptide (NPPC, P23582)
 atrial natriuretic peptide (NPPA,
P01160) brain natriuretic peptide
(NPPB, P16860) [207]
uroguanylin (GUCA2B, Q16661) >
guanylin (GUCA2A, Q02747)
atrial natriuretic peptide (NPPA, P01160) >
C-type natriuretic peptide (NPPC, P23582)
≥ brain natriuretic peptide (NPPB, P16860)
[207]
Endogenous agonists atrial natriuretic peptide (NPPA, P01160)
(Binding) [172], brain natriuretic peptide
(NPPB, P16860) (Binding) [172],
mutant ANP [150]
C-type natriuretic peptide (NPPC, P23582)
(Binding) [207]
guanylin (GUCA2A, Q02747) (Binding),
uroguanylin (GUCA2B, Q16661) (Binding)
–
Selective agonists Dendroaspis natriuretic peptide [199],
PL-3994 [50], cenderitide [145], sANP
[172]
cenderitide [145], vosoritide [136] linaclotide [24, 82],
E. coli heat-stable enterotoxin (STa) [24],
plecanatide [195]
cANF4-23 [138]
Endogenous antagonists – – – osteocrin (OSTN, P61366) [155]
Selective antagonists A-71915 (pKi 9.2–9.5) [45],
[Asu7,23’]β-ANP-(7-28) (pKi 7.5) [105],
HS-142-1 [158], anantin [229, 238]
peptide P19 (pKd 7.8) [47], HS-142-1
[158], [Ser11](N-CNP,C-ANP)pBNP2-15
[47], compound C10 [7]
– AP811 (Binding) (pKi 9.3) [221],
M372049 [91]
Labelled ligands [125I]ANP (human) (Agonist) [125I]CNP (human) [125I]Sta (Agonist) [80] [125I]ANP (human)
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Nomenclature Guanylyl cyclase-D Guanylyl cyclase-E Guanylyl cyclase-F Guanylyl cyclase-G
Common abbreviation GC-D GC-E GC-F GC-G
HGNC, UniProt – GUCY2D, Q02846 GUCY2F, P51841 GUCY2GP, –
Localisation – Retinal photoreceptors Retinal photoreceptors Grüneberg ganglion
Principal function(s) – Vision/phototransduction Vision/phototransduction Thermosensation
Endogenous ligands – – – Cold
Comments Pseudogene in humans – – Pseudogene in humans
Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
Catalytic receptors→ Receptor guanylyl cyclase (RGC) family→ Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
Overview: Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
(GTP diphosphate-lyase (cyclising)), E.C. 4.6.1.2, is a heterodimer
comprising a β1 subunit and one of two alpha subunits (α1, α2)
giving rise to two functionally indistinguishable isoforms, GC-1
(α1β1) and GC-2 (α2β1) [186, 247]. A haem group is associated
with the β subunit and is the target for the endogenous ligand
NO, and, potentially, carbon monoxide [60].
Nomenclature Guanylyl cyclase, α1β1 Guanylyl cyclase, α2β1
Common abbreviation GC-1 GC-2
Subunits Guanylyl cyclase β1 subunit, Guanylyl cyclase α1 subunit Guanylyl cyclase β1 subunit, Guanylyl cyclase α2 subunit
EC number 4.6.1.2 4.6.1.2
Endogenous ligands NO NO
Selective activators praliciguat (pEC50 6.6) [225], YC-1 [60, 114, 186], cinaciguat [apo-GC-1] [204],
olinciguat [25], riociguat [202, 203]
YC-1 [114, 186], cinaciguat [apo-GC-2] [204], olinciguat [25], riociguat [202, 203]
Selective inhibitors NS 2028 (pIC50 8.1) [170] – Bovine, ODQ (pIC50 7.5) [65] ODQ
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Comments: The polysaccharide obtained from fermentation of
Aureobasidium species, HS-142-1, acts as an antagonist at both
GC-A and GC-B receptors [158]. GC-D and GC-G have been
pre orted to be activated intracellularly by guanylyl cyclase-
activating protein 1 (GUCA1A, P43080) and guanylyl cyclase-
activating protein (GUCA1B, Q9UMX6). GC-D and GC-G may
be activated by atmospheric levels of CO2 through the forma-
tion of intracellular bicarbonate ions [29, 92]. GC-G may be
activated at cooler temperatures (20-25 C) through apparent°
stabilisation of the dimer [28].
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Nomenclature Guanylyl cyclase α1 subunit Guanylyl cyclase α2 subunit Guanylyl cyclase β1 subunit Guanylyl cyclase β2 subunit
HGNC, UniProt GUCY1A1, Q02108 GUCY1A2, P33402 GUCY1B1, Q02153 GUCY1B2, O75343
Comments: ODQ also shows activity at other haem-containing proteins [56], while YC-1 may also inhibit cGMP-hydrolysing phosphodiesterases [59, 62].
Further reading on Receptor guanylyl cyclase (RGC) family
Kuhn M. (2016) Molecular Physiology of Membrane Guanylyl Cyclase Receptors. Physiol. Rev. 96:
751-804 [PMID:27030537]
Papapetropoulos A et al. (2015) Extending the translational potential of targeting NO/cGMP-
regulated pathways in the CVS. Br. J. Pharmacol. 172: 1397-414 [PMID:25302549]
Santhekadur PK et al. (2017) The multifaceted role of natriuretic peptides in metabolic syndrome.
Biomed. Pharmacother. 92: 826-835 [PMID:28599248]
Vanhoutte PM et al. (2016) Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of
the Endothelium-Derived Vasodilator Mediator. Circ. Res. 119: 375-96 [PMID:27390338]
Volpe M et al. (2016) The natriuretic peptides system in the pathophysiology of heart failure: from
molecular basis to treatment. Clin. Sci. 130: 57-77 [PMID:26637405]
Waldman SA et al. (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders.
Gut 67: 1543-1552 [PMID:29563144]
Receptor tyrosine kinases (RTKs)
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)
Overview: Receptor tyrosine kinases (RTKs), a family of cell-
surface receptors, which transduce signals to polypeptide and pro-
tein hormones, cytokines and growth factors are key regulators of
critical cellular processes, such as proliferation and differentiation,
cell survival and metabolism, cell migration and cell cycle control
[14, 67, 219]. In the human genome, 58 RTKs have been identi-
ﬁed, which fall into 20 families [125].
All RTKs display an extracellular ligand binding domain, a single
transmembrane helix, a cytoplasmic region containing the pro-
tein tyrosine kinase activity (occasionally split into two domains
by an insertion, termed the kinase insertion), with juxta-
membrane and C-terminal regulatory regions. Agonist binding
to the extracellular domain evokes dimerization, and sometimes
oligomerization, of RTKs (a small subset of RTKs forms multi-
mers even in the absence of activating ligand). This leads to
autophosphorylation in the tyrosine kinase domain in a trans
orientation, serving as a site of assembly of protein complexes and
stimulation of multiple signal transduction pathways, including
phospholipase C-γ, mitogen-activated protein kinases and phos-
phatidylinositol 3-kinase [219].
RTKs are of widespread interest not only through physiological
functions, but also as drug targets in many types of cancer and
other disease states. Many diseases result from genetic changes
or abnormalities that either alter the activity, abundance, cellular
distribution and/or regulation of RTKs. Therefore, drugs thatmod-
ify the dysregulated functions of these RTKs have been developed
which fall into two categories. One group is often described as ‘bi-
ologicals’, which block the activation of RTKs directly or by chelat-
ing the cognate ligands, while the second are small molecules
designed to inhibit the tyrosine kinase activity directly.
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Type I RTKs: ErbB (epidermal growth factor) receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type I RTKs: ErbB (epidermal growth factor) receptor family
Overview: ErbB family receptors are Class I receptor tyrosine ki-
nases [73]. ERBB2 (also known as HER-2 or NEU) appears to act as
an essential partner for the other members of the family without
itself being activated by a cognate ligand [74]. Ligands of the ErbB
family of receptors are peptides, many of which are generated by
proteolytic cleavage of cell-surface proteins. HER/ErbB is the vi-
ral counterpart to the receptor tyrosine kinase EGFR. All family
members heterodimerize with each other to activate downstream
signalling pathways and are aberrantly expressed inmany cancers,
particularly forms of breast cancer and lung cancer. Mutations in
the EGFR are responsible for acquired resistance to tyrosine kinase
inhibitor chemotherapeutics.
Nomenclature epidermal growth factor receptor erb-b2 receptor tyrosine kinase 2 erb-b2 receptor tyrosine kinase 3 erb-b2 receptor tyrosine kinase 4
Common abbreviation EGFR HER2 HER3 HER4
HGNC, UniProt EGFR, P00533 ERBB2, P04626 ERBB3, P21860 ERBB4, Q15303
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands EGF (EGF, P01133) (Binding), HB-EGF
(HBEGF, Q99075) (Binding), TGFα (TGFA,
P01135) (Binding), amphiregulin (AREG,
P15514) (Binding), betacellulin (BTC,
P35070) (Binding), epigen (EPGN, Q6UW88)
(Binding), epiregulin (EREG, O14944)
(Binding)
– neuregulin-1 (NRG1, Q02297), neuregulin-2
(NRG2, O14511)
HB-EGF (HBEGF, Q99075), betacellulin (BTC,
P35070), epiregulin (EREG, O14944),
neuregulin-1 (NRG1, Q02297), neuregulin-2
(NRG2, O14511), neuregulin-3 (NRG3,
P56975), neuregulin-4 (NRG4, Q8WWG1)
Inhibitors afatinib (pKd 9.6) [42], tesevatinib (pIC50
9.5) [67], afatinib (pIC50 8–9.3) [37, 126]
poziotinib (pIC50 8.3) [164], CP-724714
(pIC50 7.9) [76], tesevatinib (pIC50 7.8) [67],
BMS-690514 (pIC50 7.7) [141]
– poziotinib (pIC50 7.6) [164]
Antibodies necitumumab (Binding) (pKd 9.5) [134],
cetuximab (Binding) (pKd 9.4) [70]
pertuzumab (Inhibition) (pIC50 >8) [106],
trastuzumab (Inhibition)
– –
Comments: [125I]EGF (human) has been used to label the ErbB1 EGF receptor. The extracellular domain of ErbB2 can be targetted by the antibodies trastuzumab and pertuzumab to inhibit ErbB family
action. The intracellular ATP-binding site of the tyrosine kinase domain can be inhibited by GW583340 (7.9-8.0, [66]), geﬁtinib, erlotinib and tyrphostins AG879 and AG1478.
Further reading on Type I RTKs: ErbB (epidermal growth factor) receptor family
Kobayashi Y et al. (2016) Not all epidermal growth factor receptor mutations in lung cancer are
created equal: Perspectives for individualized treatment strategy. Cancer Sci. 107: 1179-86
[PMID:27323238]
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Type II RTKs: Insulin receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type II RTKs: Insulin receptor family
Overview: The circulating peptide hormones insulin (INS,
P01308) and the related insulin-like growth factors (IGF) activate
Class II receptor tyrosine kinases [73], to evoke cellular responses,
mediated through multiple intracellular adaptor proteins. Excep-
tionally amongst the catalytic receptors, the functional receptor
in the insulin receptor family is derived from a single gene prod-
uct, cleaved post-translationally into two peptides, which then
cross-link via disulphide bridges to form a heterotetramer. In-
triguingly, the endogenous peptide ligands are formed in a
parallel fashion with post-translational processing producing a
heterodimer linked by disulphide bridges. Signalling through the
receptors is mediated through a rapid autophosphorylation event
at intracellular tyrosine residues, followed by recruitment of mul-
tiple adaptor proteins, notably IRS1 (P35568), IRS2 (Q9Y4H2),
SHC1 (P29353), GRB2 (P62993) and SOS1 (Q07889).
Serum levels of free IGFs are kept low by the action of IGF binding
proteins (IGFBP1-5, P08833, P18065, P17936, P22692, P24593),
which sequester the IGFs; overexpression of IGFBPs may induce
apoptosis, while IGFBP levels are also altered in some cancers.
Nomenclature Insulin receptor Insulin-like growth factor I receptor Insulin receptor-related receptor
Common abbreviation InsR IGF1R IRR
HGNC, UniProt INSR, P06213 IGF1R, P08069 INSRR, P14616
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Inhibitors – BMS-754807 (pIC50 8.7) [235], GSK-1838705A (pIC50
8.7) [188], GSK-1838705A (pKd 8.1) [42], PQ401 (pIC50
>6) [61], AG 1024 (pIC50 4.7) [181]
–
Selective inhibitors – NVP-AEW541 (pIC50 9.4) [64] –
Endogenous agonists insulin (INS, P01308) insulin-like growth factor 1 (IGF1, P05019),
insulin-like growth factor 2 (IGF2, P01344)
–
Comments: There is evidence for low potency binding and ac-
tivation of insulin receptors by IGF1. IGF2 also binds and ac-
tivates the cation-independent mannose 6-phosphate receptor
(also known as the insulin-like growth factor 2 receptor; IGF2R;
P11717), which lacks classical signalling capacity and appears to
subserve a trafﬁcking role [139]. INSRR, which has a much more
discrete localization, being predominant in the kidney [117], cur-
rently lacks a cognate ligand or evidence for functional impact.
Antibodies targetting IGF1, IGF2 and the extracellular portion of
the IGF1 receptor are in clinical trials.
PQ401 inhibits the insulin-like growth factor receptor [5], while
BMS-536924 inhibits both the insulin receptor and the insulin-
like growth factor receptor [234].
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Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
Overview: Type III RTKs include PDGFR, CSF-1R (Ems), Kit and FLT3, which function as homo- or heterodimers. Endogenous ligands of PDGF receptors are homo- or heterodimeric: PDGFA, PDGFB,
VEGFE and PDGFD (PDGFD, Q9GZP0) combine as homo- or heterodimers to activate homo- or heterodimeric PDGF receptors. SCF is a dimeric ligand for KIT. Ligands for CSF1R are either monomeric or
dimeric glycoproteins, while the endogenous agonist for FLT3 is a homodimer.
Nomenclature platelet derived growth factor receptor alpha platelet derived growth factor receptor beta KIT proto-oncogene, receptor tyrosine kinase
Common abbreviation PDGFRα PDGFRβ Kit
HGNC, UniProt PDGFRA, P16234 PDGFRB, P09619 KIT, P10721
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands PDGF PDGF –
Inhibitors PP121 (pIC50 8.7) [4], crenolanib (pKd 8.7) [87],
ENMD-2076 (pIC50 7.2) [177]
crenolanib (pKd 8.5) [87], SU-14813 (pIC50 8.4) [175],
famitinib (pIC50 8.4) [30], sunitinib (pIC50 8.2) [112],
sunitinib (pKi 8.1) [152]
sunitinib (pKd 9.4) [42], famitinib (pIC50 8.7) [30],
masitinib (pKd 8.1) [42], SU-14813 (pIC50 7.8) [175],
AKN-028 (pIC50 7.5) [53], sorafenib (pIC50 7.2) [233]
Selective inhibitors CP-673451 (pIC50 8) [184] CP-673451 (pIC50 9) [184] –
Endogenous agonists – – stem cell factor (KITLG, P21583) [217]
Nomenclature colony stimulating factor 1 receptor fms related tyrosine kinase 3
Common abbreviation CSFR FLT3
HGNC, UniProt CSF1R, P07333 FLT3, P36888
EC number 2.7.10.1 2.7.10.1
Endogenous ligands G-CSF (CSF3, P09919), GM-CSF (CSF2, P04141), M-CSF (CSF1, P09603) Fms-related tyrosine kinase 3 ligand (FLT3LG, P49771)
Inhibitors JNJ-28312141 (pIC50 9.2) [140], Ki-20227 (pKd 9.1) [42], Ki-20227 (pIC50 8.7) [169],
GW-2580 (pKd 8.7) [42], JNJ-28312141 (pKd 8.5) [42]
AC710 (pKd 9.3) [132], linifanib (pKd 9.2) [42], crenolanib (pKd 9.1) [87], ENMD-2076
(pIC50 8.5) [177], tandutinib (pKd 8.5) [42], tandutinib (pIC50 6.7) [108]
Selective inhibitors GW-2580 (pIC50 7.2) [36] G749 (pIC50 9.4) [122]
Comments Upregulation of CSF1R expression is associated with migroglial activation and immune
pathology in Alzhermer’s disease (AD) [71, 77]. Pharmacological inhibition of CSF1R with
GW-2580 reduces microglial proliferation and prevents disease progression in a mouse
model of AD, but this does not correlate with amyloid-β plaque numbers [171].
5’-ﬂuoroindirubinoxime has been described as a selective FLT3 inhibitor [31].
Comments: Various small molecular inhibitors of type III RTKs have been described, including imatinib and nilotinib (targetting PDGFR, KIT and CSF1R); midostaurin and AC220 (quizartinib; FLT3), as
well as pan-type III RTK inhibitors such as sunitinib and sorafenib [176]; 5’-ﬂuoroindirubinoxime has been described as a selective FLT3 inhibitor [2].
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Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family
Overview: VEGF receptors are homo- and heterodimeric
proteins, which are characterized by seven Ig-like loops in their
extracellular domains and a split kinase domain in the cyto-
plasmic region. They are key regulators of angiogenesis and
lymphangiogenesis; as such, they have been the focus of drug
discovery for conditions such as metastatic cancer. Splice variants
of VEGFR1 and VEGFR2 generate truncated proteins limited to
the extracellular domains, capable of homodimerisation and bind-
ing VEGF ligands as a soluble, non-signalling entity. Ligands
at VEGF receptors are typically homodimeric. VEGFA (VEGFA,
P15692) is able to activate VEGFR1 homodimers, VEGFR1/2 het-
erodimers and VEGFR2/3 heterodimers. VEGFB (VEGFB, P49765)
and placental growth factor (PGF, P49763) activate VEGFR1 ho-
modimers, while VEGFC (VEGFC, P49767) and VEGFD (VEGFD,
O43915) activate VEGFR2/3 heterodimers and VEGFR3 homod-
imers, and, following proteolysis, VEGFR2 homodimers.
Nomenclature fms related tyrosine kinase 1 kinase insert domain receptor fms related tyrosine kinase 4
Common abbreviation VEGFR-1 VEGFR-2 VEGFR-3
HGNC, UniProt FLT1, P17948 KDR, P35968 FLT4, P35916
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands VEGFA (VEGFA, P15692), VEGFB (VEGFB, P49765) VEGFA (VEGFA, P15692), VEGFC (VEGFC, P49767),
VEGFE (PDGFC, Q9NRA1)
VEGFC (VEGFC, P49767), VEGFD (VEGFD, O43915),
VEGFE (PDGFC, Q9NRA1)
Inhibitors SU-14813 (pIC50 8.7) [175], CEP-11981 (pIC50 8.5)
[94], semaxanib (pIC50 8.1) [15]
cabozantinib (pIC50 10.5) [239], axitinib (pIC50 9.6)
[123], foretinib (pIC50 8.2–9.1) [162], cediranib (pKd 9)
[42], tesevatinib (pIC50 8.8) [67], motesanib (pKd 8.6)
[42], famitinib (pIC50 8.3) [30], axitinib (pKd 8.2) [42]
tesevatinib (pIC50 8.1) [67], sunitinib (pIC50 8.1) [109],
nintedanib (pIC50 7.9) [90]
Sub/family-selective inhibitors pazopanib (pIC50 8) [83] pazopanib (pKd 7.8) [42], pazopanib (pIC50 7.5) [83] pazopanib (pIC50 7.3) [83]
Antibodies – ramucirumab (Antagonist) (pIC50 9) [137] –
Comments: The VEGFR, as well as VEGF ligands, have been targeted by antibodies and tyrosine kinase inhibitors. DMH4 [57], Ki8751 [116] and ZM323881, a novel inhibitor of vascular endothelial
growth factor-receptor-2 tyrosine kinase activity [231] are described as VEGFR2-selective tyrosine kinase inhibitors. Bevacizumab is a monoclonal antibody directed against VEGF-A, used clinically for the
treatment of certain metastatic cancers; an antibody fragment has been used for wet age-related macular degeneration.
Type V RTKs: FGF (ﬁbroblast growth factor) receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type V RTKs: FGF (ﬁbroblast growth factor) receptor family
Overview: Fibroblast growth factor (FGF) family receptors act as
homo- and heterodimers, and are characterized by Ig-like loops in
the extracellular domain, in which disulphide bridges may form
across protein partners to allow the formation of covalent dimers
which may be constitutively active. FGF receptors have been
implicated in achondroplasia, angiogenesis and numerous con-
genital disorders. At least 22members of the FGF gene family have
been identiﬁed in the human genome [11]. Within this group,
subfamilies of FGF may be divided into canonical, intracellular
and hormone-like FGFs. FGF1-FGF10 have been identiﬁed to act
through FGF receptors, while FGF11-14 appear to signal through
intracellular targets. Other family members are less well charac-
terized [230].
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Nomenclature ﬁbroblast growth factor receptor 1 ﬁbroblast growth factor receptor 2 ﬁbroblast growth factor receptor 3 ﬁbroblast growth factor receptor 4
Common abbreviation FGFR1 FGFR2 FGFR3 FGFR4
HGNC, UniProt FGFR1, P11362 FGFR2, P21802 FGFR3, P22607 FGFR4, P22455
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-4 (FGF4, P08620) > FGF-5
(FGF5, P12034), FGF-6 (FGF6, P10767)
[174]
FGF-1 (FGF1, P05230) > FGF-4 (FGF4,
P08620), FGF-7 (FGF7, P21781), FGF-9
(FGF9, P31371) > FGF-2 (FGF2, P09038),
FGF-6 (FGF6, P10767) [174]
FGF-10 (FGF10, O15520) [243]
FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-9 (FGF9, P31371) > FGF-4
(FGF4, P08620), FGF-8 (FGF8, P55075)
[174]
FGF-3 (FGF3, P11487)
FGF-1 (FGF1, P05230), FGF-2 (FGF2,
P09038), FGF-4 (FGF4, P08620), FGF-9
(FGF9, P31371) > FGF-6 (FGF6, P10767),
FGF-8 (FGF8, P55075) [174]
Sub/family-selective inhibitors LY2874455 (pIC50 8.6) [248] LY2874455 (pIC50 8.6) [248] LY2874455 (pIC50 8.2) [248] LY2874455 (pIC50 8.2) [248]
Selective inhibitors – – – BLU-9931 (Irreversible inhibition) (pIC50
8.5) [79]
Agonists – palifermin – –
Comments: Splice variation of the receptors can inﬂuence agonist responses. FGFRL1 (Q8N441) is a truncated kinase-null analogue.
Various antibodies and tyrosine kinase inhibitors have been developed against FGF receptors [129, 252]. PD161570 is an FGFR tyrosine kinase inhibitor [9], while PD173074 has been described to inhibit
FGFR1 and FGFR3 [200].
Type VI RTKs: PTK7/CCK4
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type VI RTKs: PTK7/CCK4
Overview: The PTK7 receptor is associated with polarization of epithelial cells and the development of neural structures. Sequence analysis suggests that the gene product is catalytically inactive as a
protein kinase, although there is evidence for a role in Wnt signalling [180].
Nomenclature protein tyrosine kinase 7 (inactive)
Common abbreviation CCK4
HGNC, UniProt PTK7, Q13308
EC number 2.7.10.1
Comments: Thus far, no selective PTK7 inhibitors have been described.
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Type VII RTKs: Neurotrophin receptor/Trk family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type VII RTKs: Neurotrophin receptor/Trk family
Overview: The neurotrophin receptor family of RTKs include
trkA, trkB and trkC (tropomyosin-related kinase) receptors, which
respond to NGF, BDNF and neurotrophin-3, respectively. They
are associated primarily with proliferative and migration effects
in neural systems. Various isoforms of neurotrophin re-
ceptors exist, including truncated forms of trkB and trkC,
which lack catalytic domains. p75 (TNFRSF16, also known
as nerve growth factor receptor), which has homologies with
tumour necrosis factor receptors, lacks a tyrosine kinase domain,
but can signal via ceramide release and nuclear factor κB (NF-κB)
activation. Both trkA and trkB contain two leucine-rich regions
and can exist in monomeric or dimeric forms.
Nomenclature neurotrophic receptor tyrosine kinase 1 neurotrophic receptor tyrosine kinase 2 neurotrophic receptor tyrosine kinase 3
Common abbreviation trkA trkB trkC
HGNC, UniProt NTRK1, P04629 NTRK2, Q16620 NTRK3, Q16288
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands NGF (NGF, P01138) > neurotrophin-3 (NTF3, P20783) BDNF (BDNF, P23560), neurotrophin-4 (NTF4, P34130)
> neurotrophin-3 (NTF3, P20783)
neurotrophin-3 (NTF3, P20783)
Inhibitors LOXO-195 (pIC50 >9.3) [165], compound 2c (pIC50
8.9) [226], milciclib (pIC50 7.3) [17]
– –
Sub/family-selective inhibitors AZD1332 (pIC50 >8.3) [6], GNF-5837 (pIC50 8) [2] AZD1332 (pIC50 >8.3) [6], GNF-5837 (pIC50 8.1) [2] AZD1332 (pIC50 >8.3) [6], GNF-5837 (pIC50 8.1) [2]
Comments: [125I]NGF (human) and [125I]BDNF (human) have
been used to label the trkA and trkB receptor, respectively. p75 in-
ﬂuences the binding of NGF (NGF, P01138) and neurotrophin-3
(NTF3, P20783) to trkA. The ligand selectivity of p75 appears
to be dependent on the cell type; for example, in sympathetic
neurones, it binds neurotrophin-3 (NTF3, P20783) with compa-
rable afﬁnity to trkC [44].
Small molecule agonists of trkB have been described, includ-
ing LM22A4 [148], while ANA12 has been described as a non-
competitive antagonist of BDNF binding to trkB [27]. GNF5837 is
a family-selective tyrosine kinase inhibitor [2], while the tyrosine
kinase activity of the trkA receptor can be inhibited by GW441756
(pIC = 8.7, [50 236]) and tyrphostin AG879 [168].
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Type VIII RTKs: ROR family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type VIII RTKs: ROR family
Overview: Members of the ROR family appear to be activated by ligands complexing with other cell-surface proteins. Thus, ROR1 and ROR2 appear to be activated by Wnt-5a (WNT5A, P41221) binding
to a Frizzled receptor thereby forming a cell-surface multiprotein complex [75].
Nomenclature receptor tyrosine kinase like orphan receptor 1 receptor tyrosine kinase like orphan receptor 2
Common abbreviation ROR1 ROR2
HGNC, UniProt ROR1, Q01973 ROR2, Q01974
EC number 2.7.10.1 2.7.10.1
Type IX RTKs: MuSK
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type IX RTKs: MuSK
Overview: The muscle-speciﬁc kinase MuSK is associated with the formation and organisation of the neuromuscular junction from the skeletal muscle side. Agrin (AGRN, O00468) forms a complex with
low-density lipoprotein receptor-related protein 4 (LRP4, O75096) to activate MuSK [110].
Nomenclature muscle associated receptor tyrosine kinase
Common abbreviation MuSK
HGNC, UniProt MUSK, O15146
EC number 2.7.10.1
Comments: Thus far, no selective MuSK inhibitors have been described.
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Type X RTKs: HGF (hepatocyte growth factor) receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type X RTKs: HGF (hepatocyte growth factor) receptor family
Overview: HGF receptors regulate maturation of the liver in the embryo, as well as having roles in the adult, for example, in the innate immune system. HGF is synthesized as a single gene product, which
is post-translationally processed to yield a heterodimer linked by a disulphide bridge. The maturation of HGF is enhanced by a serine protease, HGF activating complex, and inhibited by HGF-inhibitor 1
(SPINT1, O43278), a serine protease inhibitor. MST1, the ligand of RON, is two disulphide-linked peptide chains generated by proteolysis of a single gene product.
Nomenclature MET proto-oncogene, receptor tyrosine kinase macrophage stimulating 1 receptor
Common abbreviation MET Ron
HGNC, UniProt MET, P08581 MST1R, Q04912
EC number 2.7.10.1 2.7.10.1
Endogenous ligands hepatocyte growth factor (HGF, P14210) macrophage stimulating protein 1 (MST1, P09603)
Inhibitors capmatinib (pIC50 9.9) [135], SGX-523 (pKd 9.7) [42], cabozantinib (pIC50 8.9) [239] BMS-777607 (pIC50 8.7) [192]
Selective inhibitors SGX-523 (pIC50 8.4) [23] –
Comments: PF04217903 is a selective Met tyrosine kinase inhibitor [38]. SU11274 is an inhibitor of the HGF receptor [189], with the possibility of further targets [5].
Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family
Overview: Members of this RTK family represented a novel structural motif, when sequenced. The ligands for this family, growth arrest speciﬁc protein 6 (GAS6, Q14393) and protein S (PROS1, P07225),
are secreted plasma proteins which undergo vitamin K-dependent post-translational modiﬁcations generating carboxyglutamate-rich domains which are able to bind to negatively-charged surfaces of
apoptotic cells.
Nomenclature AXL receptor tyrosine kinase TYRO3 protein tyrosine kinase MER proto-oncogene, tyrosine kinase
Common abbreviation Axl Tyro3 Mer
HGNC, UniProt AXL, P30530 TYRO3, Q06418 MERTK, Q12866
EC number 2.7.10.1 2.7.10.1 2.7.10.1
Endogenous ligands growth arrest speciﬁc protein 6 (GAS6, Q14393) [163],
protein S (PROS1, P07225) [206]
growth arrest speciﬁc protein 6 (GAS6, Q14393) [163],
protein S (PROS1, P07225) [206]
growth arrest speciﬁc protein 6 (GAS6, Q14393) [163]
Comments: AXL tyrosine kinase inhibitors have been described [156].
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Type XII RTKs: TIE family of angiopoietin receptors
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XII RTKs: TIE family of angiopoietin receptors
Overview: The TIE family were initially associated with formation of blood vessels. Endogenous ligands are angiopoietin-1 (ANGPT1, Q15389), angiopoietin-2 (ANGPT2, O15123), and angiopoietin-4
(ANGPT4, Q9Y264). Angiopoietin-2 (ANGPT2, O15123) appears to act as an endogenous antagonist of angiopoietin-1 function.
Nomenclature tyrosine kinase with immunoglobulin like and EGF like domains 1 TEK receptor tyrosine kinase
Common abbreviation TIE1 TIE2
HGNC, UniProt TIE1, P35590 TEK, Q02763
EC number 2.7.10.1 2.7.10.1
Endogenous ligands – angiopoietin-1 (ANGPT1, Q15389), angiopoietin-4 (ANGPT4, Q9Y264)
Type XIII RTKs: Ephrin receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XIII RTKs: Ephrin receptor family
Overview: Ephrin receptors are a family of 15 RTKs (the
largest family of RTKs) with two identiﬁed subfamilies (EphA
and EphB), which have a role in the regulation of neu-
ronal development, cell migration, patterning and angio-
genesis. Their ligands are membrane-associated proteins,
thought to be glycosylphosphatidylinositol-linked for EphA
(ephrin-A1 (EFNA1, P20827) , ephrin-A2 (EFNA2, O43921),
ephrin-A3 (EFNA3, P52797), ephrin-A4 (EFNA4, P52798) and
ephrin-A5 (EFNA5, P52803)) and 1TM proteins for Ephrin B
(ENSFM00250000002014: ephrin-B1 (EFNB1, P98172), ephrin-B2
(EFNB2, P52799) and ephrin-B3 (EFNB3, Q15768)), although the
relationship between ligands and receptors has been incompletely
deﬁned.
Nomenclature EPH receptor A1 EPH receptor A2 EPH receptor A3 EPH receptor A4 EPH receptor A5 EPH receptor A6 EPH receptor A7
Common abbreviation EphA1 EphA2 EphA3 EphA4 EphA5 EphA6 EphA7
HGNC, UniProt EPHA1, P21709 EPHA2, P29317 EPHA3, P29320 EPHA4, P54764 EPHA5, P54756 EPHA6, Q9UF33 EPHA7, Q15375
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
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Nomenclature EPH receptor A8 EPH receptor A10 EPH receptor B1 EPH receptor B2 EPH receptor B3 EPH receptor B4 EPH receptor B6
Common abbreviation EphA8 EphA10 EphB1 EphB2 EphB3 EphB4 EphB6
HGNC, UniProt EPHA8, P29322 EPHA10, Q5JZY3 EPHB1, P54762 EPHB2, P29323 EPHB3, P54753 EPHB4, P54760 EPHB6, O15197
EC number 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1 2.7.10.1
Inhibitors – – compound 66 (pIC50
9) [119]
– – tesevatinib (pIC50 8.9)
[67]
–
Type XIV RTKs: RET
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XIV RTKs: RET
Overview: Ret proto-oncogene (Rearranged during transfection) is a transmembrane tyrosine kinase enzyme which is employed as a signalling partner for members of the GDNF family receptors. Ligand-
activated GFR appears to recruit Ret as a dimer, leading to activation of further intracellular signalling pathways. Ret appears to be involved in neural crest development, while mutations may be involved
in multiple endocrine neoplasia, Hirschsprung’s disease, and medullary thyroid carcinoma.
Nomenclature ret proto-oncogene
Common abbreviation Ret
HGNC, UniProt RET, P07949
EC number 2.7.10.1
Inhibitors tamatinib (pIC50 8.3) [32]
Comments: A number of tyrosine kinase inhibitors targeting RET have been described [54].
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XIV RTKs: RET S281
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Type XV RTKs: RYK
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XV RTKs: RYK
Overview: The ‘related to tyrosine kinase receptor’ (Ryk) is structurally atypical of the family of RTKs, particularly in the activation and ATP-binding domains. RYK has been suggested to lack kinase
activity and appears to be involved, with FZD8, in the Wnt signalling system [180].
Nomenclature receptor like tyrosine kinase
Common abbreviation RYK
HGNC, UniProt RYK, P34925
EC number 2.7.10.1
Comments: Thus far, no selective RYK inhibitors have been described.
Type XVI RTKs: DDR (collagen receptor) family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XVI RTKs: DDR (collagen receptor) family
Overview: Discoidin domain receptors 1 and 2 (DDR1 and DDR2) are structurally-related membrane protein tyrosine kinases activated by collagen. Collagen is probably the most abundant protein in
man, with at least 29 families of genes encoding proteins, which undergo splice variation and post-translational processing, and may exist in monomeric or polymeric forms, producing a triple-stranded,
twine-like structure. In man, principal family members include COL1A1 (COL1A1, P02452), COL2A1 (COL2A1, P02458), COL3A1 (COL3A1, P02461) and COL4A1 (COL4A1, P02462).
Nomenclature discoidin domain receptor tyrosine kinase 1 discoidin domain receptor tyrosine kinase 2
Common abbreviation DDR1 DDR2
HGNC, UniProt DDR1, Q08345 DDR2, Q16832
EC number 2.7.10.1 2.7.10.1
Comments: The tyrosine kinase inhibitors of DDR, imatinib and nilotinib, were identiﬁed from proteomic analysis [43]. Other collagen receptors include glycoprotein VI (Q9HCN6), leukocyte-associated
immunoglobulin-like receptor 1 (Q6GTX8), leukocyte-associated immunoglobulin-like receptor 2 (Q6ISS4) and osteoclast-associated immunoglobulin-like receptor (Q8IYS5).
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XVI RTKs: DDR (collagen receptor) family S282
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Type XVII RTKs: ROS receptors
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XVII RTKs: ROS receptors
Nomenclature c-ros oncogene 1, receptor tyrosine kinase
Common abbreviation ROS
HGNC, UniProt ROS1, P08922
EC number 2.7.10.1
Comments: Crizotinib is a tyrosine kinase inhibitor, anti-cancer drug targeting ALK and ROS1.
Type XVIII RTKs: LMR family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XVIII RTKs: LMR family
Overview: The LMR kinases are unusual amongst the RTKs in possessing a short extracellular domain and extended intracellular domain (hence the ‘Lemur’ name reﬂecting the long tail). A precise
function for these receptors has yet to be deﬁned, although LMR1 was identiﬁed as a potential marker of apoptosis [63], giving rise to the name AATYK (Apoptosis-associated tyrosine kinase); while
over-expression induces differentiation in neuroblastoma cells [183].
Nomenclature apoptosis associated tyrosine kinase lemur tyrosine kinase 2 lemur tyrosine kinase 3
Common abbreviation Lmr1 Lmr2 Lmr3
HGNC, UniProt AATK, Q6ZMQ8 LMTK2, Q8IWU2 LMTK3, Q96Q04
EC number 2.7.11.1 2.7.11.1 2.7.11.1
Comments: As yet no selective inhibitors of the LMR family have been described.
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XVIII RTKs: LMR family S283
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Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family
Overview: The LTK family appear to lack endogenous ligands. LTK is subject to tissue-speciﬁc splice variation, which appears to generate products in distinct subcellular locations. ALK fusions created
by gene translocations and rearrangements are associated with many types of cancer, including large cell lymphomas, inﬂammatory myoﬁbrilastic tumours and non-small cell lung cancer [144].
Nomenclature leukocyte receptor tyrosine kinase ALK receptor tyrosine kinase
Common abbreviation LTK ALK
HGNC, UniProt LTK, P29376 ALK, Q9UM73
EC number 2.7.10.1 2.7.10.1
Inhibitors – GSK-1838705A (pIC50 9.3) [188], compound 8e (pIC50 9.1) [93], crizotinib (pIC50 9) [39], NVP-TAE684 (pKd 9)
[42], compound 25b (pIC50 8.7) [69] ceritinib (pIC50 9.7) [144]
Selective inhibitors – –
Comments – Crizotinib appears to be a selective ALK inhibitor acting on the tyrosine kinase activity [68]
Type XX RTKs: STYK1
Catalytic receptors→ Receptor kinases→ TK: Tyrosine kinase→ Receptor tyrosine kinases (RTKs)→ Type XX RTKs: STYK1
Overview: Similar to the LMR RTK family, STYK1 has a truncated extracellular domain, but also displays a relatively short intracellular tail beyond the split kinase domain. STYK1 (also known as Novel
Oncogene with Kinase-domain, NOK) has been suggested to co-localize with activated EGF receptor [48].
Nomenclature serine/threonine/tyrosine kinase 1
Common abbreviation STYK1
HGNC, UniProt STYK1, Q6J9G0
EC number 2.7.10.2
Comments: As yet, no selective inhibitors of STYK1 have been described.
Searchable database: http://www.guidetopharmacology.org/index.jsp Type XX RTKs: STYK1 S284
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Further reading on Receptor tyrosine kinases (RTKs)
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and Intracellular Signal Transduction. Annu. Rev. Biochem. 85: 573-97 [PMID:27023845]
Carvalho S et al. (2016) Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of
anti-cancer antibodies: IUPHAR Review 18. Br. J. Pharmacol. 173: 1407-24 [PMID:26833433]
De Silva DM et al. (2017) Targeting the hepatocyte growth factor/Met pathway in cancer. Biochem.
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Tan AC et al. (2017) Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug
Discov. Today 22: 72-84 [PMID:27452454]
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Receptor serine/threonine kinase (RSTK) family
Catalytic receptors→ Receptor kinases→ TKL: Tyrosine kinase-like→ Receptor serine/threonine kinase (RSTK) family
Overview: Receptor serine/threonine kinases (RTSK),
EC 2.7.11.30, respond to particular cytokines, the transforming
growth factor β (TGFβ) and bone morphogenetic protein (BMP)
families, and may be divided into two subfamilies on the basis
of structural similarities. Agonist binding initiates formation of a
cell-surface complex of type I and type II RSTK, possibly heterote-
trameric, where where both subunits express serine/threonine
kinase activity. The type I receptor serine/threonine kinases are
also known as activin receptors or activin receptor-like kinases,
ALKs, for which a systematic nomenclature has been proposed
(ALK1-7). The type II protein phosphorylates the kinase domain
of the type I partner (sometimes referred to as the signal propagat-
ing subunit), causing displacement of the protein partners, such
as the FKBP12 FK506-binding protein FKBP1A (P62942) and allow-
ing the binding and phosphorylation of particular members of the
Smad family. These migrate to the nucleus and act as complexes to
regulate gene transcription. Type III receptors, sometimes called
co-receptors or accessory proteins, regulate the signalling of the
receptor complex, in either enhancing (for example, presenting
the ligand to the receptor) or inhibitory manners. TGFβ family
ligand signalling may be inhibited by endogenous proteins, such
as follistatin (FST, P19883), which binds and neutralizes activins
to prevent activation of the target receptors.
Endogenous agonists, approximately 30 in man, are often de-
scribed as paracrine messengers acting close to the source of
production. They are characterized by six conserved cysteine
residues and are divided into two subfamilies on the ba-
sis of sequence comparison and signalling pathways activated,
the TGFβ/activin/nodal subfamily and the BMP/GDF (growth/
differentiation factor)/MIS (Müllerian inhibiting substance) sub-
family. Ligands active at RSTKs appear to be generated as large pre-
cursors which undergo complexmaturation processes [128]. Some
are known to form disulphide-linked homo- and/or heterodimeric
complexes. Thus, inhibins are α subunits linked to a variety of β
chains, while activins are combinations of β subunits.
Type I receptor serine/threonine kinases
Catalytic receptors→ Receptor kinases→ TKL: Tyrosine kinase-like→ Receptor serine/threonine kinase (RSTK) family→ Type I receptor serine/threonine kinases
Overview: The type I receptor serine/threonine kinases are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7).
Nomenclature activin A receptor
type IL
activin A receptor
type 1
bone morphogenetic
protein receptor type IA
activin A receptor
type 1B
transforming growth
factor beta receptor 1
bone morphogenetic
protein receptor type IB
activin A receptor
type 1C
Common abbreviation ALK1 ALK2 BMPR1A ALK4 TGFBR1 BMPR1B ALK7
HGNC, UniProt ACVRL1, P37023 ACVR1, Q04771 BMPR1A, P36894 ACVR1B, P36896 TGFBR1, P36897 BMPR1B, O00238 ACVR1C, Q8NER5
EC number 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30
Inhibitors – ML347 (pIC50 7.5) [52] – – LY2109761 (pKi 7.4)
[151], compound 15b
(pIC50 7.1) [127]
– –
Selective inhibitors – – – vactosertib (pIC50 7.9)
[103]
vactosertib (pIC50 8)
[103]
– –
Further reading on Type I receptor serine/threonine kinases
Batlle E et al. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer Immunity
50: 924-940
Searchable database: http://www.guidetopharmacology.org/index.jsp Type I receptor serine/threonine kinases S286
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Type II receptor serine/threonine kinases
Catalytic receptors→ Receptor kinases→ TKL: Tyrosine kinase-like→ Receptor serine/threonine kinase (RSTK) family→ Type II receptor serine/threonine kinases
Nomenclature activin A receptor type 2A activin A receptor type 2B anti-Mullerian hormone
receptor type 2
bone morphogenetic protein
receptor type 2
transforming growth
factor beta receptor 2
Common abbreviation ActR2 ActR2B MISR2 BMPR2 TGFBR2
HGNC, UniProt ACVR2A, P27037 ACVR2B, Q13705 AMHR2, Q16671 BMPR2, Q13873 TGFBR2, P37173
EC number 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30 2.7.11.30
Antibodies – bimagrumab (Binding) (pKd
11.8) [10]
– – –
Further reading on Type II receptor serine/threonine kinases
Batlle E et al. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer Immunity
50: 924-940
Type III receptor serine/threonine kinases
Catalytic receptors→ Receptor kinases→ TKL: Tyrosine kinase-like→ Receptor serine/threonine kinase (RSTK) family→ Type III receptor serine/threonine kinases
Nomenclature transforming growth factor beta receptor 3
Common abbreviation TGFBR3
HGNC, UniProt TGFBR3, Q03167
RSTK functional heteromers
Catalytic receptors→ Receptor kinases→ TKL: Tyrosine kinase-like→ Receptor serine/threonine kinase (RSTK) family→ RSTK functional heteromers
Overview: For the receptors listed below, the exact combination of subunits forming the functional heteromeric receptors is unknown.
Searchable database: http://www.guidetopharmacology.org/index.jsp RSTK functional heteromers S287
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Nomenclature Transforming growth factor β receptor Bone morphogenetic protein receptors
Subunits transforming growth factor beta receptor 1 (Type I),
transforming growth factor beta receptor 3 (Type III),
transforming growth factor beta receptor 2 (Type II)
bone morphogenetic protein receptor type IB (Type I), activin A receptor type 2B (Type II),
activin A receptor type 2A (Type II), activin A receptor type IL (Type I),
activin A receptor type 1 (Type I), bone morphogenetic protein receptor type IA (Type I),
bone morphogenetic protein receptor type 2 (Type II)
Coupling Smad2, Smad3 [160, 198] Smad1, Smad5, Smad8 [160, 198]
Endogenous agonists TGFβ1 (TGFB1, P01137), TGFβ2 (TGFB2, P61812), TGFβ3 (TGFB3, P10600) BMP-10 (BMP10, O95393), BMP-2 (BMP2, P12643), BMP-4 (BMP4, P12644), BMP-5 (BMP5,
P22003), BMP-6 (BMP6, P22004), BMP-7 (BMP7, P18075), BMP-8A (BMP8A, Q7Z5Y6),
BMP-8B (BMP8B, P34820), BMP-9 (GDF2, Q9UK05)
Nomenclature Growth/differentiation factor receptors Activin receptors Anti-Müllerian hormone receptors
Subunits transforming growth factor beta receptor 1 (Type I),
bone morphogenetic protein receptor type IB (Type I),
activin A receptor type 2B (Type II),
activin A receptor type 2A (Type II),
activin A receptor type 1C (Type I),
bone morphogenetic protein receptor type IA (Type I),
activin A receptor type 1B (Type I),
bone morphogenetic protein receptor type 2 (Type II)
activin A receptor type 2B (Type II),
activin A receptor type 2A (Type II),
activin A receptor type 1C (Type I),
activin A receptor type 1B (Type I)
anti-Mullerian hormone receptor type 2 (Type II),
bone morphogenetic protein receptor type IB (Type I),
activin A receptor type 1 (Type I),
bone morphogenetic protein receptor type IA (Type I)
Coupling Smad1, Smad5, Smad8 [160, 198] Smad2, Smad3 [198] Smad1, Smad5, Smad8 [160, 198]
Endogenous agonists growth/differentiation factor-1 (GDF1, P27539),
growth/differentiation factor-10 (GDF10, P55107),
growth/differentiation factor-3 (GDF3, Q9NR23),
growth/differentiation factor-7 (GDF7, Q7Z4P5),
growth/differentiation factor-9 (GDF9, O60383)
activin A (INHBA, P08476), activin AB (INHBA INHBB, P08476
P09529), activin B (INHBB, P09529), inhibin A (INHA INHBA,
P05111 P08476)
Müllerian inhibiting substance (AMH, P03971)
Comments – Activin receptors are heteromeric complexes comprising
activin receptor type I and type II subunits.
–
Further reading on RSTK functional heteromers
Batlle E et al. (2019) Transforming Growth Factor-β Signaling in Immunity and Cancer Immunity
50: 924-940
Comments on Receptor serine/threonine kinase (RSTK) family: A number of endogenous inhibitory ligands have been identiﬁed for RSTKs, including BMP-3 (BMP3, P12645), inhibin α (INHA,
P05111), inhibin βC (INHBC, P55103) and inhibin βE (INHBE, P58166).
An appraisal of small molecule inhibitors of TGFβ and BMP signalling concluded that TGFβ pathway inhibitors were more selective than BMP signalling inhibitors [223]. The authors conﬁrmed the
selectivity of TGF-beta RI inhibitor III to inhibit TGFβ signalling through ALK4, ALK5, ALK7 [40]. Dorsomorphin inhibits BMP signalling through ALK2 and ALK3, it also inhibits AMP kinase [250].
Smads were identiﬁed as mammalian orthologues of Drosophila genes termed “mothers against decapentaplegic” and may be divided into Receptor-regulated Smads (R-Smads, including Smad1, Smad2,
Smad3, Smad5 and Smad8), Co-mediated Smad (Co-Smad, Smad4) and Inhibitory Smads (I-Smad, Smad6 and Smad7). R-Smads form heteromeric complexes with Co-Smad. I-Smads compete for binding
of R-Smad with both receptors and Co-Smad.
Searchable database: http://www.guidetopharmacology.org/index.jsp RSTK functional heteromers S288
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Nomenclature HGNC gene symbol Uniprot ID Other names
Smad1 SMAD1 Q15797 JV4-1, MADH1, MADR1
Smad2 SMAD2 Q15796 JV18-1, MADH2, MADR2
Smad3 SMAD3 P84022 HsT17436, JV15-2, MADH3
Smad4 SMAD4 Q13485 DPC4, MADH4
Smad5 SMAD5 Q99717 Dwfc, JV5-1, MADH5
Smad6 SMAD6 O43541 HsT17432, MADH6, MADH7
Smad7 SMAD7 O15105 MADH7, MADH8
Smad8 SMAD9 O15198 MADH6, MADH9
Further reading on Receptor serine/threonine kinase (RSTK) family
Budi EH et al. (2017) Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity
and Functional Versatility. Trends Cell Biol. 27: 658-672 [PMID:28552280]
Chen W et al. (2016) Immunoregulation by members of the TGFβ superfamily. Nat. Rev. Immunol.
16: 723-740 [PMID:27885276]
Heger J et al. (2016) Molecular switches under TGFβ signalling during progression from cardiac
hypertrophy to heart failure. Br. J. Pharmacol. 173: 3-14 [PMID:26431212]
Luo JY et al. (2015) Regulators and effectors of bone morphogenetic protein signalling in the car-
diovascular system. J. Physiol. (Lond.) 593: 2995-3011 [PMID:25952563]
Macias MJ et al. (2015) Structural determinants of Smad function in TGF-β signaling. Trends Biochem.
Sci. 40: 296-308 [PMID:25935112]
Morrell NW et al. (2016) Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev
Cardiol 13: 106-20 [PMID:26461965]
Neuzillet C et al. (2015) Targeting the TGFβ pathway for cancer therapy. Pharmacol. Ther. 147:
22-31 [PMID:25444759]
van der Kraan PM. (2017) The changing role of TGFβ in healthy, ageing and osteoarthritic joints.
Nat Rev Rheumatol 13: 155-163 [PMID:28148919]
Receptor tyrosine phosphatase (RTP) family
Catalytic receptors→ Receptor tyrosine phosphatase (RTP) family
Overview: Receptor tyrosine phosphatases (RTP) are cell-surface proteins with a single TM region and intracellular phosphotyrosine phosphatase activity. Many family members exhibit constitutive
activity in heterologous expression, dephosphorylating intracellular targets such as Src tyrosine kinase (SRC) to activate signalling cascades. Family members bind components of the extracellular matrix
or cell-surface proteins indicating a role in intercellular communication.
Nomenclature RTP Type A RTP Type B RTP Type C RTP Type D RTP Type E RTP Type F RTP Type G
HGNC, UniProt PTPRA, P18433 PTPRB, P23467 PTPRC, P08575 PTPRD, P23468 PTPRE, P23469 PTPRF, P10586 PTPRG, P23470
Putative endogenous ligands – – galectin-1 (LGALS1,
P09382) [224]
netrin-G3 ligand
(LRRC4B, Q9NT99)
[118]
– netrin-G3 ligand
(LRRC4B, Q9NT99)
[118]
contactin-3 (CNTN3,
Q9P232), contactin-4
(CNTN4, Q8IWV2),
contactin-5 (CNTN5,
O94779), contactin-6
(CNTN6, Q9UQ52) [16]
Inhibitors – – – – – illudalic acid (pIC50
5.9) [131]
compound 1 (pKi 5.6)
[197]
Searchable database: http://www.guidetopharmacology.org/index.jsp Receptor tyrosine phosphatase (RTP) family S289
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Nomenclature RTP Type H RTP Type J RTP Type K RTP Type M RTP Type N RTP Type N2 RTP Type O
HGNC, UniProt PTPRH, Q9HD43 PTPRJ, Q12913 PTPRK, Q15262 PTPRM, P28827 PTPRN, Q16849 PTPRN2, Q92932 PTPRO, Q16827
Putative endogenous ligands – – galectin-3 (LGALS3,
P17931),
galectin-3 binding protein
(LGALS3BP, Q08380)
[111]
– – – –
Inhibitors – – – compound 8a (pIC50
5.2) [85]
– – –
Nomenclature RTP Type Q RTP Type R RTP Type S RTP Type T RTP Type U RTP Type Z1
HGNC, UniProt PTPRQ, Q9UMZ3 PTPRR, Q15256 PTPRS, Q13332 PTPRT, O14522 PTPRU, Q92729 PTPRZ1, P23471
Putative endogenous ligands – – chondroitin sulphate
proteoglycan 3 (NCAN,
O14594), netrin-G3 ligand
(LRRC4B, Q9NT99) [118, 196]
– – contactin-1 (CNTN1,
Q12860), pleiotrophin
(PTN, C9JR52) (acts as a
negative regulator) [16,
153]
Inhibitors – – compound 7b (pIC50 5.4)
[78], 7-BIA (pIC50 4.4) [218]
– – –
Further reading on Receptor tyrosine phosphatase (RTP) family
Papadimitriou E et al. (2016) Pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta as
regulators of angiogenesis and cancer. Biochim. Biophys. Acta 1866: 252-265 [PMID:27693125]
Stanford SM et al. (2017) Targeting Tyrosine Phosphatases: Time to End the Stigma. Trends Pharma-
col. Sci. 38: 524-540 [PMID:28412041]
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Tumour necrosis factor (TNF) receptor family
Catalytic receptors→ Tumour necrosis factor (TNF) receptor family
Overview: Dysregulated TNFR signalling is associated with many inﬂammatory disorders, including some forms of arthritis and inﬂammatory bowel disease, and targeting TNF has been an effective
therapeutic strategy in these diseases and for cancer immunotherapy [19, 20, 194].
Nomenclature tumor necrosis factor
receptor 1
tumor necrosis factor
receptor 2
lymphotoxin β receptor OX40 CD40 Fas decoy receptor 3
Systematic nomenclature TNFRSF1A TNFRSF1B TNFRSF3 TNFRSF4 TNFRSF5 TNFRSF6 TNFRSF6B
Common abbreviation TNFR1 TNFR2 – – – – –
HGNC, UniProt TNFRSF1A, P19438 TNFRSF1B, P20333 LTBR, P36941 TNFRSF4, P43489 CD40, P25942 FAS, P25445 TNFRSF6B, O95407
Adaptor proteins TRADD TRAF1, TRAF2, TRAF5 TRAF3, TRAF4, TRAF5 TRAF1, TRAF2, TRAF3,
TRAF5
TRAF1, TRAF2, TRAF3,
TRAF5, TRAF6
FADD –
Endogenous ligands lymphotoxin-α (LTA,
P01374),
tumour necrosis factor
membrane form (TNF,
P01375),
tumour necrosis factor
shed form (TNF,
P01375)
lymphotoxin-α (LTA,
P01374),
tumour necrosis factor
membrane form (TNF,
P01375)
LIGHT (TNFSF14,
O43557),
lymphotoxin β2α1
heterotrimer (LTA LTB,
P01374 Q06643)
OX-40 ligand (TNFSF4,
P23510)
CD40 ligand (CD40LG,
P29965)
Fas ligand (FASLG,
P48023)
–
Ligands – – – compound 1 (Binding)
(pIC50 5.9) [201]
– – –
Comments – – – The OX40/OX40L pair is
involved in late T-cell
costimulatory signaling
and both are transiently
expressed following
antigen recognition,
and blocking
OX40/OX40L is
reported to prevent the
development of disease
in in vivo autoimmune
and inﬂammatory
disease models [228]
– – Decoy receptor for
LIGHT (TNFSF14,
O43557), TL1A
(TNFSF15, O95150) and
Fas ligand (FASLG,
P48023).
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Nomenclature CD27 CD30 4-1BB death receptor 4 death receptor 5 decoy receptor 1 decoy receptor 2
Systematic nomenclature TNFRSF7 TNFRSF8 TNFRSF9 TNFRSF10A TNFRSF10B TNFRSF10C TNFRSF10D
Common abbreviation – – – DR4 DR5 – –
HGNC, UniProt CD27, P26842 TNFRSF8, P28908 TNFRSF9, Q07011 TNFRSF10A, O00220 TNFRSF10B, O14763 TNFRSF10C, O14798 TNFRSF10D, Q9UBN6
Adaptor proteins TRAF2, SIVA TRAF1, TRAF2, TRAF3,
TRAF5
TRAF1, TRAF2, TRAF3 FADD FADD – –
Endogenous ligands CD70 (CD70, P32970) CD30 ligand (TNFSF8,
P32971)
4-1BB ligand (TNFSF9,
P41273)
TRAIL (TNFSF10,
P50591)
– – –
Endogenous agonists – – – – TRAIL (TNFSF10,
P50591) [251]
– –
Agonists – – – SC-67655 [81] – – –
Antibodies – brentuximab vedotin
(Inhibition)
– – tigatuzumab (Agonist)
(pKd ∼8.5) [251]
– –
Comments – – – – – Decoy receptor for
TRAIL (TNFSF10,
P50591).
Decoy receptor for
TRAIL (TNFSF10,
P50591).
Nomenclature receptor activator
of NF-kappa B
osteoprotegerin death receptor 3 TWEAK receptor TACI BAFF receptor herpes virus entry
mediator
Systematic nomenclature TNFRSF11A TNFRSF11B TNFRSF25 TNFRSF12A TNFRSF13B TNFRSF13C TNFRSF14
Common abbreviation RANK OPG DR3 – – BAFF-R HVEM
HGNC, UniProt TNFRSF11A, Q9Y6Q6 TNFRSF11B, O00300 TNFRSF25, Q93038 TNFRSF12A, Q9NP84 TNFRSF13B, O14836 TNFRSF13C, Q96RJ3 TNFRSF14, Q92956
Adaptor proteins TRAF1, TRAF2, TRAF3,
TRAF5, TRAF6
– TRADD TRAF1, TRAF2, TRAF3 TRAF2, TRAF5, TRAF6 TRAF3 TRAF2, TRAF3, TRAF5
Endogenous ligands RANK ligand
(TNFSF11, O14788)
– TL1A (TNFSF15,
O95150)
TWEAK (TNFSF12,
O43508)
APRIL (TNFSF13,
O75888), BAFF
(TNFSF13B, Q9Y275)
BAFF (TNFSF13B,
Q9Y275)
B and T lymphocyte
attenuator (BTLA,
Q7Z6A9), LIGHT
(TNFSF14, O43557),
lymphotoxin-α (LTA,
P01374)
Comments – Acts as a decoy receptor
for RANK ligand
(TNFSF11, O14788) and
possibly for TRAIL
(TNFSF10, P50591).
The only known
TNFSF ligand for DR3
is TNF-like protein 1A
(TL1A) [225].
– – – –
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Nomenclature nerve growth factor receptor B cell maturation antigen glucocorticoid-induced
TNF receptor
toxicity and JNK inducer RELT death receptor 6
Systematic nomenclature TNFRSF16 TNFRSF17 TNFRSF18 TNFRSF19 TNFRSF19L TNFRSF21
Common abbreviation – BCMA GITR TAJ – DR6
HGNC, UniProt NGFR, P08138 TNFRSF17, Q02223 TNFRSF18, Q9Y5U5 TNFRSF19, Q9NS68 RELT, Q969Z4 TNFRSF21, O75509
Adaptor proteins TRAF2, TRAF4, TRAF6 TRAF1, TRAF2, TRAF3,
TRAF5, TRAF6
TRAF1, TRAF2, TRAF3,
SIVA
TRAF1, TRAF2, TRAF3, TRAF5 TRAF1 TRADD
Endogenous ligands NGF (NGF, P01138) (pIC50 6)
[101], BDNF (BDNF,
P23560), neurotrophin-3
(NTF3, P20783),
neurotrophin-4 (NTF4,
P34130)
APRIL (TNFSF13,
O75888), BAFF
(TNFSF13B, Q9Y275)
TL6 (TNFSF18, Q9UNG2) lymphotoxin-α (LTA,
P01374)
– –
Comments One of the two receptor
types for the neurotrophins
(factors that stimulate
neuronal cell survival and
differentiation). The other
family of neurotrophin
receptors are the Trk family of
receptor tyrosine kinases.
– – Believed to be essential
during embryonic
development.
Abundant in hematologic
tissues. Selective receptor for
TNF receptor-associated
factor 1 (TRAF1). Activates
the NF-κB pathway.
–
Nomenclature TNFRSF22 TNFRSF23 ectodysplasin A2 isoform receptor ectodysplasin 1, anhidrotic receptor
Systematic nomenclature – – TNFRS27 –
HGNC, UniProt – – EDA2R, Q9HAV5 EDAR, Q9UNE0
Adaptor proteins – – TRAF1, TRAF3, TRAF6 TRAF1, TRAF2, TRAF3
Endogenous ligands – – ectodysplasin A2 (EDA, Q92838) [240] ectodysplasin A1 (EDA, Q92838) [240]
Comments Only identiﬁed in mouse to date. A
potential decoy receptor for the cytotoxic
ligand TNFSF10/TRAIL. Does not contain a
cytoplasmic death domain so does not
induce apoptosis, and does not activate
the NF-κB signalling pathway.
Only identiﬁed in mouse to date. A
potential decoy receptor for the cytotoxic
ligand TNFSF10/TRAIL. Does not contain a
cytoplasmic death domain so does not
induce apoptosis, and does not activate
the NF-κB signalling pathway.
Receptor for the EDA-A2 isoform of
ectodysplasin encoded by the anhidrotic
ectodermal dysplasia (EDA) gene.
Cell surface receptor for ectodysplasin A (a
morphogen involved in the development
of ectodermal tissues, including skin, hair,
nails, teeth, and sweat glands).
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Comments: TNFRSF1A is preferentially activated by the
shed form of TNF ligand, whereas the membrane-bound form
of TNF serves to activate TNFRSF1A and TNFRSF1B equally.
The neurotrophins nerve growth factor (NGF (NGF, P01138)),
brain-derived neurotrophic factor (BDNF (BDNF, P23560)),
neurotrophin-3 (NTF3, P20783) (NTF3) and neurotrophin-4
(NTF4, P34130) (NTF4) are structurally unrelated to the TNF lig-
and superfamily but exert some of their actions through the “low
afﬁnity nerve growth factor receptor” (NGFR (TNFRSF16)) as well
as through the TRK family of receptor tyrosine kinases. The en-
dogenous ligands for EDAR and EDA2R are, respectively, themem-
brane (Q92838[1-391]) and secreted (Q92838[160-391]) isoforms
of Ectodysplasin-A (EDA, Q92838).
Further reading on Tumour necrosis factor (TNF) receptor family
Blaser H et al. (2016) TNF and ROS Crosstalk in Inﬂammation. Trends Cell Biol. 26: 249-261
[PMID:26791157]
Croft M et al. (2017) Beyond TNF: TNF superfamily cytokines as targets for the treatment of
rheumatic diseases. Nat Rev Rheumatol 13: 217-233 [PMID:28275260]
Kalliolias GD et al. (2016) TNF biology, pathogenic mechanisms and emerging therapeutic strate-
gies. Nat Rev Rheumatol 12: 49-62 [PMID:26656660]
Olesen CM et al. (2016) Mechanisms behind efﬁcacy of tumor necrosis factor inhibitors in inﬂam-
matory bowel diseases. Pharmacol. Ther. 159: 110-9 [PMID:26808166]
von Karstedt S et al. (2017) Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.
Nat. Rev. Cancer 17: 352-366 [PMID:28536452]
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